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Blood cells have a limited life-span and must be continuously replenished throughout 
mammalian life, in a process termed hematopoiesis. Hematopoiesis is maintained by the 
proliferation and differentiation of a very small population of pluripotent hematopoietic 
stem cells (HSCs) and their progeny that reside in bone marrow (BM) (Figure 1). Together 
they provide a steady-supply of red blood cells (that enable O2/CO2 exchange), thrombocytes 
(needed for blood clot formation), and leukocytes (essential for the protection against 
pathogens).
Chemo- and radiotherapy (chemo/radiotherapy) are among the most commonly used 
treatments for patients with cancer. Both inhibit cell division by differing modes of action, 
and once combined, can synergistically arrest growth and induce death of rapidly dividing 
malignant (cancerous) cells. However, this means that “healthy” non-malignant cells 
undergoing DNA replication are also affected, which may result in unwanted deleterious 
effects, such as BM suppression.
BM suppression, also known as myelosuppression, generally refers to the depletion of 
hematopoietic cells: red blood cells (anemia), thrombocytes (thrombocytopenia), and 
leukocytes (leukopenia). Anemia is associated with fatigue, dizziness, and heart palpitations, 
while thrombocytopenia is commonly accompanied by increased risks of bruises and 
bleedings. Leukopenia in particular is concerning since it leaves patients susceptible to 
opportunistic infections (including viral infections and fungal infections and fever/febrile 
episodes. The time needed for patients to achieve full hematopoietic recovery can be 
considerable and is a significant cause of morbidity, especially for patients with a delayed 
hematopoietic recovery. 
In response to chemo/radiotherapy-induced damage, HSCs become activated to generate 
progenitors and mature blood cells to replenish those lost during injury. However, how 
and what drives this activation of HSCs remains incompletely understood. Over the past 
two decades we have come to realize that HSC function can be greatly influenced by its 
surrounding microenvironment in the BM. The BM microenvironment for HSCs, often 
referred to as the HSC niche, can be considered an ancillary meshwork of heterogeneous 
cells that may facilitate HSC fate by various mechanisms, such as paracrine signaling 
mediated by secretion of growth factors (cytokines). 
Given the key role of niche cells in HSC maintenance and proliferation, it is reasonable to 
think that a better understanding of the HSC niche, specifically upon regeneration (after 
chemotherapeutic injury), may lead to the identification of niche cells and niche-derived 
factors that promote hematopoietic recovery. This may enable us to develop novel 
treatments that reduce the time needed for patients to recover from chemotherapy-
induced myelosuppression.
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1.1.1 Homeostatic hematopoiesis
Under homeostatic conditions, the hematopoietic system depends on a small pool of 
pluripotent HSCs. In general, HSCs rarely divide and can generate virtually identical HSCs (a 
hallmark ability termed self-renewal) or progeny that are more highly proliferative but also 
more lineage-committed. These progenitors in turn mature into terminally differentiated 
cells that constitute the entire blood system. A simplified view of hematopoiesis (Figure 1) 
is to consider the hematopoietic system as a hierarchy of different blood cells that either fall 
under the myeloid or lymphoid branch with HSCs at the apex. 
HSCs are heterogeneous and can be subdivided into long-term and short-term HSCs (LT-
HSCs and ST-HSCs) based on their self-renewal capacity and degree of quiescence, with 
the more dormant LT-HSCs giving rise to multipotent progenitors (MPPs) via the more 
proliferative ST-HTCs (Passegue et al., 2003). MPPs lack self-renewal ability but retain full-
lineage differentiation potential. MPPs in turn differentiate into oligo-potent progenitors, 
namely the common lymphoid progenitor (CLP) and the common myeloid progenitor 
(CMP). Further downstream, the CLP develops into cells of the lymphoid lineage, such as 
the natural killer (NK) cells, B and T lymphocytes. The CMP gives rise to the granulocytic/
macrophage progenitor (GMP) and the megakaryocytic/erythroid progenitor (MEP) that 
together will generate granulocytes (neutrophils, eosinophils, and basophils), mononuclear 
cells (monocytes, macrophages), megakaryocytes, and erythrocytes.
Erythrocytes, also known as red blood cells (RBCs), provide O2/CO2 exchange and are the 
most abundant cell-type in peripheral blood (PB). Granulocytes and mononuclear cells are 
the first line of defense against pathogens and foreign material (innate immunity), and are 
involved in the removal of damaged cells. Megakaryocytes associate with BM sinusoidal 
vessels and release thrombocytes (platelets) in the peripheral circulation, which are essential 
for clot formation in case of damage to blood vessels. The lymphoid cells provide long-term 
memory for protection against recurring pathogens (adaptive immunity). 
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Figure 1. Simplified overview of hematopoiesis. Continuous production of mature blood cells and components 
depends on the self-renewal and differentiation of HSCs. HSCs give rise to MPPs that develop into more committed 
progenitors. CMPs give rise to erythrocytes, platelets, and myeloid cells, whereas CLPs differentiate into lymphoid 
cells. The myeloid cells consist of monocytes/macrophages, and granulocytes, the latter consisting of eosinophils, 
basophils and neutrophils. The lymphoid cells include the NK cells, and the B and T lymphocytes. Collectively, the 
granulocytes and lymphoid cells are referred to as leukocytes/white blood cells.
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Figure 2. Structural organization of BM in long bones of mice. Adapted from (Nombela-Arrieta and Manz, 2017). 
a.  Simplified overview of the BM microarchitecture in the mouse femur. The central artery (CA) divides into 
arterioles (Art) that extend to the endosteal surface which develop into smaller endosteal capillaries (purple) 
that connect to the complex sinusoidal network (blue) which merges into the central sinus (CS) in the middle 
of the BM cavity. The distinct blood vessels are aligned by various stromal cells. Bone-degrading cells, called 
osteoclasts (Oc), line the endosteal surface. Adipocytes (Adip) also reside in the marrow and progressively 
increase upon aging. 
b.  1. While most hematopoietic stem cells (HSCs) are adjacent to the sinusoids (blue), some HSCs preferentially 
localize to arteries (red). Arteries are enwrapped by sympathetic nervous system (SNS) fibers (purple) and 
Nestin-GFPbrightNG2+ cells (green), whereas sinusoids are associated with LEPR+Nestin-GFPdim cells. 2. Endosteal 
capillaries (purple) are associated with Osterix+ cells (Osx, orange). Bone-lining osteoprogenitors/osteoblasts 
(Ob) regulate lymphoid progenitor (Imm B) number. 
1.1.2 HSC niches
Architecture of the BM microenvironment 
Whether hematopoietic stem and progenitor cells (HSPCs) become activated (to differentiate 
and proliferate) or remain in a dormant state is partially determined by extracellular 
cues derived from their BM microenvironment. These extrinsic cues include secretion of 
regulatory factors, cell-cell interactions, interaction with the extracellular matrix, and 
regulation of reactive species oxygen (ROS) levels. In long bones, the architecture of BM is 
characterized by a complex and dynamic arrangement of hematopoietic niches with distinct 
compositions (Figure 2A). 
BM is a very cell-dense and highly vascularized tissue (Draenert and Draenert, 1980; 
Nombela-Arrieta and Manz, 2017; Ramasamy, 2017). Blood is supplied to BM by multiple 
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arteries which divide into smaller arterioles that move towards the endosteal region (the 
inner-surface of bone), where they further divide into small-diameter endosteal arterioles/
capillaries. These endosteal capillaries transit into downstream sinusoidal vessels, which 
form a complex network that extends inwards to the medullary cavity, and merge with the 
central sinus/vein. Despite high vascular density, BM is relatively hypoxic (<32 mmHg), with 
the lowest oxygen tensions found near sinusoids in the central cavity, due to high oxygen 
demand associated with its high cellular density (Spencer et al., 2014). Many niche cells 
are adjacent to these diverse BM blood vessels (Crane et al., 2017), which, besides oxygen, 
also provide access to nutrients and other metabolites derived from circulating blood, and 
regulate cellular trafficking. Of note, both bone and BM are extensively innervated by the 
sympathetic nervous system (SNS). Furthermore, while human BM hardly contains any fat 
at birth, adipocytes (fat-producing cells) gradually increase with age, leading to a shift from 
red (hematopoietic-rich) marrow to yellow (fatty) marrow. 
The discovery of surface markers for HSCs and BM microenvironmental cells, as well as, 
advances in imaging techniques and transgenic mouse models, have enabled studies to 
better define the cellular components and function of the HSC niche. Studies in mice suggest 
that within adult BM numerous cell-types constitute the HSC niche, with the majority being 
non-hematopoietic (stromal) cells and an increasingly recognized minor subset consisting of 
(mature) hematopoietic cells, as will be discussed in more detail in the following section. In 
particular, BM blood vessels seem to take on a critical role, which will be highlighted in their 
own separate section following the introduction of the HSC niche. 
 HSC-regulatory factors derived from niche cells essential for HSC maintenance
One of the ways to define niche cells is by their ability to synthesize factors that sustain 
HSC survival. Stem cell factor (SCF) and C-X-C motif chemokine ligand 12 (CXCL12) are the 
quintessential example of such HSC-regulatory factors and are probably among the best 
characterized niche-derived cytokines. 
SCF is an agonist for the c-KIT receptor (Williams et al., 1990), which is expressed by HSCs 
(Kiel et al., 2005). Membrane-bound and soluble forms of SCF exist, and in vivo studies 
revealed that transgenic mice only expressing the soluble form of SCF have decreased HSC 
number (Barker, 1994, 1997), indicating that the membrane-bound form is critical for HSC 
maintenance. This finding also implies that SCF-expressing niche cells are in direct cell-cell 
contact with HSCs. 
CXCL12, in addition to regulating HSC number, is also required for HSC retention in BM 
(Ara et al., 2003; Sugiyama et al., 2006; Tzeng et al., 2011). Mutant mice lacking CXCL12 
fail to initiate hematopoiesis in fetal BM due to impaired colonialization by LT-HSCs (Ara et 
al., 2003). Additional genetic studies showed that abrogating expression of CXCL12 or its 
receptor CXCR4 in adulthood lead to depletion of BM HSCs (Sugiyama et al., 2006; Tzeng et 
al., 2011). 
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Advances in mouse genetics have enabled conditional and inducible abrogation of CXCL12, 
SCF, and other genes encoding for HSC regulatory factors in restricted cell populations by 
means of various Cre recombinases expressed under the control of (in theory) cell type-
specific promoters. This has become an essential tool to test if and when expression of a 
single factor by a candidate cell type is required for HSC regulation.
HSC maintenance during steady-state: Osteoblasts
Osteoblasts reside at the endosteal surface of BM and are indispensable for de novo bone 
formation, secreting numerous extracellular proteins, such as type 1 collagen, osteocalcin 
(Ocn), and alkaline phosphatase (Figure 2B). Initially, in vivo studies using genetically 
engineered mice suggested that osteoblasts were important for regulating HSC number 
(Calvi et al., 2003; Zhang et al., 2003). Mice deficient for bone morphogenetic protein 
receptor type IA (BMPR1A) have an increased number of spindle-shaped N-cadherin-
expressing osteoblastic cells which was associated with increased HSC number. Using 
5-bromodeoxyuridine (BrdU)-labelling, researchers found that BrdU-retaining (a surrogate 
marker for LT-HSCs) cells were adjacent to these osteoblasts (Zhang et al., 2003). In line with 
these findings was the observation that expansion of osteoblasts, mediated by constitutively 
active PTH/ PTHrP receptor (PPR) signaling that was restricted to maturing osteoblastic cells, 
also lead to more HSCs (Calvi et al., 2003). 
However, follow-up studies using other transgenic mouse lines and more specific markers 
for HSCs have since disputed a direct role for osteoblasts in regulating HSC number under 
homeostatic conditions. While conditional ablation of maturing osteoblasts in transgenic 
mice (that express herpesvirus thymidine kinase under control of a rat type 1 collagen 
promotor (Col 2.3)) upon ganciclovir injection eventually resulted in loss of BM HSCs (Visnjic 
et al., 2004); subsequent analyses showed that the decrease in HSC number (28 days 
post-injection) is preceded by early loss of B-lymphoid progenitors (8 days post-injection), 
suggesting that osteoblasts play a more direct role in B lymphopoiesis rather than in HSC 
regulation (Zhu et al., 2007). 
This view was later supported by two companion papers from the laboratories of Drs. Daniel 
Link (using Ocn-Cre transgenic mice) and Sean Morrison (using Col2.3-Cre transgenic mice) 
both demonstrating that conditional deletion of CXCL12 in osteoblasts did not deplete HSC 
number (Ding et al., 2012; Greenbaum et al., 2013). Furthermore, it had been shown that 
BM osteoblasts lack SCF expression and conditional deletion of SCF in mature osteoblasts 
had no effect on HSCs (Ding et al., 2012). Lastly, the group lead by Sean Morrison also 
demonstrated that c-kit+Sca-1+Lin- BM cells with distinct expression of signaling lymphocyte 
activation molecules (SLAM) – CD150+, CD48-, and CD41- – enriched for functional HSCs 
and the majority of these cells localized close to sinusoidal blood vessels, rather than the 
endosteum (Kiel et al., 2005) (Figure 2B).
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Taken together, these studies still support a regulatory function of osteoblasts in unperturbed 
hematopoiesis, albeit at more committed stages of hematopoietic differentiation and 
perhaps not directly at HSC level. Hence, focus had shifted to other cellular components in 
the BM to uncover which niches directly control the HSC population.
HSCs niches under steady-state conditions: Perivascular stromal cells
Multipotency is not limited to HSCs in the BM. BM also contains stromal cells that form 
fibroblast colonies in culture (colony-forming unit-fibroblasts (CFU-Fs)) that exhibit multi-
lineage differentiation capacity; fibroblasts expand extensively and can differentiate into 
cells of different mesenchymal fates, including osteoblasts, adipocytes, and chondrocytes 
(ex vivo). These multipotent bone marrow stromal cells (BMSCs) are very heterogeneous in 
situ (ability to give rise to different mesenchymal lineages, ancestry, and marker expression) 
and can be found on the abluminal surface of BM blood vessels (Crisan et al., 2008; Sacchetti 
et al., 2007). Intriguingly, ex vivo expanded BMSCs have previously been shown to form 
ectopic BM upon transplantation, forming donor-derived bone housing recipient-derived 
hematopoietic cells, making them attractive HSC niche candidates (Friedenstein et al., 1974). 
Considering that the majority of immunophenotypic HSCs were found to be associated 
with sinusoidal blood vessels (Kiel et al., 2005), and also with CXCL12-abundant reticular 
(CAR) cells – the main source of BM CXCL12 – which themselves often surrounded sinusoids 
(Sugiyama et al., 2006), studies started dissecting (1) the precise role of perivascular 
stromal cells in HSC maintenance and (2) their relation to BMSCs due to similar perivascular 
localization and reticular morphology. 
In 2010, two independent studies by Mendez-Ferrer et al and Omatsu et al were among 
the first to demonstrate that perivascular stromal cells in postnatal marrow of mice are 
essential for regulating BM HSCs number and that some physiologically resembled BMSCs 
(Méndez-Ferrer et al., 2010; Omatsu et al., 2010). Using Nes-GFP transgenic mice, in 
which GFP expression is driven by the second intronic enhancer of nestin, the group of 
Paul Frenette demonstrated that Nes-GFP+ cells marked perivascular stromal cells that 
expressed CXCL12 and SCF, and ablation of Nestin-expressing cells lead to reduced BM 
HSC number and HSC mobilization to the spleen. Provocatively, Nes-GFP+ cells (1%) were 
enriched for CFU-Fs and were able to differentiate into osteoblasts and chondrocytes in 
vivo, and proved to be serially transplantable: demonstrating their self-renewal capacity 
(Méndez-Ferrer et al., 2010). Congruent with these findings were the observations that (1) 
CAR cells depletion in postnatal marrow lead to a decreased HSC number and (2) CAR cells 
were able to differentiate into adipocytes and osteogenic cells in vivo (Omatsu et al., 2010). 
These landmark studies were the first to provide proof of principle that HSC and BMSC 
biology may be coupled under physiological conditions. 
Subsequent work demonstrated that the Nes-GFP+ population could be subdivided in two 
populations based on GFP expression and their specific perivascular localization (Kunisaki 
et al., 2013). Nes-GFPbright cells marked rare peri-arteriolar cells and were labelled by the 
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pericyte marker NG2, while Nes-GFPdim cells were much more abundant reticular stromal 
cells that largely associated with sinusoidal vessels (peri-sinusoidal). Though the authors 
also confirmed that the majority of the HSCs were closest to sinusoids, a subset of quiescent 
HSCs localized closer than expected to Nes-GFPbright-enwrapped arterioles assuming a 
random distribution pattern (Figure 2B). Of note, most of the CFU-F content was confined 
to Nes-GFPdim cells, despite exhibiting lower CFU-F frequency (1% vs 4%), due to their higher 
total cell count (3,500 vs 300 cells per femur). 
Meanwhile the studies from the laboratories of Drs. Daniel Link and Sean Morrison, in which 
researchers systematically abolished CXCL12 and SCF expression in candidate niche cells, 
demonstrated that Prx1-Cre and LepR-Cre activity also marked perivascular stromal cells 
that expressed both CXCL12 and SCF in postnatal marrow (Ding and Morrison, 2013; Ding 
et al., 2012; Greenbaum et al., 2013). It was initially suggested that LepR-Cre cells partially 
overlapped with Nes-GFP+ cells (Ding et al., 2012). In fact, it was later demonstrated that 
LepR-Cre cells highly overlapped (98%) with Nes-GFP+ cells (Zhou et al., 2014) and that 
80-90% Nes-GFPdim cells coincided with LepR-Cre cells (Kunisaki et al., 2013; Zhou et al., 
2014). Nes-GFPbright cells did not strongly overlap with LepR-Cre (Kunisaki et al., 2013), only 
9% of Nes-GFPbright cells coincided with LepR-Cre (Zhou et al., 2014). In addition, Zhou et al 
showed that nearly all Leptin receptor (LepR)-expressing cells in postnatal BM were positive 
for Prx1-Cre and vice versa. 
Conditional deletion of CXCL12 and SCF revealed distinct contributions of perivascular 
stromal cells to HSC maintenance; abrogation of CXCL12 expression in Prx1-Cre and LepR-
Cre transgenic mice induced HSC mobilization in both cases, but only HSC depletion in Prx1-
Cre mice (Ding and Morrison, 2013; Greenbaum et al., 2013), whereas abrogation of SCF 
expression in LepR-Cre did deplete HSC number (Ding and Morrison, 2013). This was later 
confirmed in follow-up work by the group of Dr. Paul Fernette, in which they reproduced 
the effects of LepR-Cre mediated SCF and CXCL12 deletion on HSC maintenance. They also 
showed that inducible targeted deletion of CXCL12 induced in 2 week-old NG2-CreER mice 
(supposedly targeting peri-arteriolar Nes-GFPbright stromal cells), resulted in HSC number 
depletion, while observing no effect of SCF deletion on HSC number. 
Although it was also demonstrated that the majority of LepR-expressing perivascular cells 
enwrapped sinusoids, a minority was also found around some arterioles. Intriguingly, 10% 
of the BM cells marked by LepR-Cre gave rise to CFU-Fs that were able to differentiate into 
osteoblasts, adipocytes and chondrocytes ex vivo (Zhou et al., 2014). Lineage-tracing studies 
revealed that LepR-Cre cells arose postnatally and were a major source of bone and fat in 
postnatal BM. 
Collectively, these studies further redefined the role of perivascular stromal cells as key 
components of the HSC niche and their associated BMSC activity, and indicated that 
perivascular stromal cells are diverse and consist of distinct subsets that exhibit specific 
spatial characteristics in the BM, and differentially contribute to the HSC niche (Figure 2B).
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HSCs niches under steady-state conditions: Other cells 
Hematopoietic cells derived from HSCs can convey signals to HSCs and thereby create a 
feedback loop. Three-dimensional whole-mount imaging demonstrated that a subset of 
HSCs associate with megakaryocytes (Bruns et al., 2014). Depletion of megakaryocytes leads 
to HSC proliferation and expansion, and megakaryocytes-derived chemokine C-X-C motif 
ligand 4 (CXCL4) (Bruns et al., 2014) and TGFβ-1 (Zhao et al., 2014) have been suggested to 
contribute to the maintenance of HSC quiescence (Figure 2B). 
Recent work by Hur et al also proposed that HSC quiescence is controlled by niche-
mediated activation of TGFβ signaling in HSCs. These researchers suggested that activation 
of TGFβ–SMAD3 signaling was dependent on stabilization of CD82 (expressed on dormant 
HSCs) by engaging with its binding partner DARC/CD234, which is expressed by a subset 
of macrophages (Hur et al., 2016). Previously, macrophages were thought to have more 
indirect contributions on HSCs by acting via niche cells. In mice, HSC lodgment in the BM was 
severely disrupted upon targeted depletion of CD169+ macrophages and this coincided with 
a substantial loss of CXCL12, indicating that macrophages may act via niche cells by regulating 
their expression of HSC-retention factors (such as CXCL12 by Nestin-GFP+ cells) (Chow et al., 
2011). CXCL12 expression can also be regulated by the removal of aged neutrophils from 
the circulation and their subsequent engulfment by macrophages (Casanova-Acebes et al., 
2013), suggesting that interactions between mature hematopoietic cells (macrophages and 
neutrophils) can affect the HSC niche. A more direct role for (mature) myeloid cells was 
suggested by a recent study that demonstrated that myeloid cells form a spatial cluster 
around a subset of HSCs and conferred their quiescence by histamine secretion (Chen et 
al., 2017).
Differentiated lymphoid cells have also been implicated to play a role in hematopoiesis. 
IFNγ produced by cytotoxic CD8+ T cells was shown to induce IL-6 production by BMSCs, 
and thereby enhanced proliferation and myeloid differentiation of early hematopoietic 
progenitor cells during acute viral infection (Schürch et al., 2014). More recently, a subset 
of FoxP3+ regulatory T cells marked by CD150 expression was shown to closely associate 
with HSCs and maintained HSC quiescence by protecting HSCs from oxidative stress under 
homeostatic conditions (Hirata et al., 2018).
The SNS also seems to play an important role in HSC regulation. Adrenergic nerves from 
the SNS have been shown to control HSC egress into the circulation by regulating cyclical 
expression of niche-derived CXCL12 (in a circadian manner) (Méndez-Ferrer et al., 2008) 
and it was later revealed that these sympathetic nerves innervated Nes-GFP+ stromal cells 
(Méndez-Ferrer et al., 2010). Furthermore, it has been reported that sympathetic nerve-
associated nonmyelinating Schwann cells can promote HSC maintenance by regulating 
proteolytic activation of latent TGFβ in the BM (Yamazaki et al., 2011).
Lastly, adipocytes have been suggested to play a negative role in the HSC niche; adipocyte-
rich BM (such as the vertebrae of the mouse tails) was shown to contain fewer HSPCs 
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compared to adipocyte-free BM (vertebrae of the thorax) (Naveiras et al., 2009), but direct 
evidence, particularly during homeostasis, is lacking (Figure 2). 
HSC niches in humans
Knowledge on the specific cellular components of the human HSC niche (in adult BM) has 
until recently been limited compared to that generated by studies performed on mice. 
Much attention has been placed on identifying human BMSCs considering data from murine 
models strongly argue that mesenchymal progenitor cells fulfill a crucial role in regulating 
HSC function. 
Ironically, one of the first studies that managed to prospectively isolate human BMSCs 
with bona-fide self-renewal capacity and the ability to create a hematopoietic-supporting 
microenvironment, preceded the transgenic mice studies that initially identified BMSCs 
as important HSC niche components (Méndez-Ferrer et al., 2010; Zhou et al., 2014). By 
using a single positive marker, CD146, the group of Paolo Bianco demonstrated that CD146 
labelled adventitial (abluminal surface of blood vessels) reticular cells in adult BM that were 
enriched for CFU-Fs and upon xenogenic transplantation in mice, formed heterotopic ossicles 
harboring (1) murine-derived hematopoietic tissue and (2) phenotypically identical CD146+ 
BMSCs (Sacchetti et al., 2007). Later it was revealed that CD146 marked a perivascular 
subset of the CD271-expressing BMSCs, while the CD271+ subset lacking CD146 expression 
exhibited an endosteal localization, and together contained virtually all the CFU-Fs in adult 
BM (Tormin et al., 2011). Both CD271+ subsets co-localized with CD34+ HSPCs in situ and 
were equally capable of forming ectopic bone and BM upon transplantation (Tormin et al., 
2011). Of note, work of the group of Dr. Simón Méndez-Ferrer suggested that a combination 
of the cell surface markers CD105 and CD146 could be used to prospectively isolate the 
human equivalent of Nestin-GFP+ cells. CD105+CD146+ cells obtained from adult BM were 
able to generate mesenchymal spheres in vitro that were able to support the expansion of 
HPCs capable of engrafting immunocompromised mice (Isern et al., 2014).
Despite the considerable effort spent on identifying human BMSCs, evidence for their 
hematopoietic-supporting capacity and potential underlying mechanisms is still relatively 
lacking compared to that generated by studies using genetically engineered mice. It remains 
to be seen to what extent findings in mice are relevant for human biology. 
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1.1.3 HSCs and their niche during regeneration 
Impact of chemo/radiotherapeutic stress on the hematopoietic system 
In the treatment of various malignancies, chemotherapy and radiotherapy are often used 
to eradicate malignant cells, but can also have unwanted harmful effects on hematopoiesis. 
In general, chemo/radiotherapy works by causing DNA damage and consequently inducing 
senescence or death of cells. The severity of the damage to the hematopoietic system 
depends on the treatment regimen. 
Ionizing radiation (IR) can induce DNA damage in cells by the formation of reactive oxygen 
species (ROS). Cells harbor antioxidant systems to scavenge excess ROS, but can become 
overwhelmed if ROS reach high enough levels. This overabundance of ROS can damage 
macromolecules within cells (such as lipids, proteins, and DNA) and if not timely repaired, 
may lead to cell death (Azzam et al., 2012). In severe cases, this oxidative stress persists 
because pro-inflammatory cytokines are often up-regulated by ROS, and these re-inforce 
the production of ROS (cytokine storm) (Kim et al., 2014). IR can also directly damage cells 
by inducing double-stranded breaks in DNA. 
Chemotherapy makes use of cytotoxic drugs that inhibit cell division. Chemotherapeutic 
agents are diverse, and include alkylating agents, antimetabolites, and anthracyclines 
(Cheung-Ong et al., 2013). Alkylating agents, such as cyclophosphamide act by forming 
cross-links in DNA double-helix strands, while antimetabolites, like cytarabine, compete 
with nucleosides for incorporation into DNA. Anthracyclines can interact with DNA in 
different ways, including intercalation (insertion between the base pairs) and poisoning of 
topoisomerase II.
In general, cycling cells are in particular sensitive to the effects of chemo/radiotherapy, 
which means that committed myeloid progenitors giving rise to mature blood cells are 
more affected compared to the more dormant/quiescent HSCs (Lerner and Harrison, 
1990; Mohrin et al., 2010). Consequently, peripheral blood cell counts often decrease 
after chemotherapy, and exhibit a progressive decline based on the intrinsic lifespan of the 
cell, with granulocytes declining prior to platelets followed by erythrocytes (Mauch et al., 
1995). This sequence and rate of decline of peripheral blood cells is similar for radiotherapy. 
The resulting granulocytopenia and thrombocytopenia leave patients especially at risk for 
opportunistic infections and bleedings, and are major cause of morbidity in the treatment 
of cancer. 
Upon stress conditions dormant HSCs become activated to replenish lost cells (Wilson et 
al., 2008), but how the niche might mediate dormant HSC activation has remained obscure 
until recently. Spurred on by the increased knowledge on which BM microenvironmental 
cells constitute the HSC niche and with advances in the tools to identify specific subsets of 
HSPC populations, studies have started focusing on dissecting the role of the niche cells in 
BM regeneration in response to chemoradiotherapeutic stress. 
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Impact of chemoradiotherapeutic stress on the HSC niche and consequences
Cytotoxic damage resulting from chemo/radiotherapy is not limited to the hematopoietic 
system, micro-environmental cells in the BM can also suffer damage depending on the 
treatment regimen. 
Cao et al reported that femur irradiation at a dose of 20 Gray can robustly alter the BM 
architecture of mice and saw that BM exhibited increased adipogenesis, reduced CFU-F 
efficiency, and a disrupted vasculature network (Cao et al., 2011). Similarly, chemotherapeutic 
agents, such as cyclophosphamide and methotrexate (an antimetabolite), have also been 
associated with increased marrow adipocyte content, bone loss, and regression of BM 
blood vessels in murines (Georgiou et al., 2012; Shirota and Tavassoli, 1991). 
Osteolineage cells
Although recent work has toned down the importance of osteoblasts in regulating HSC 
number during homeostasis, numerous studies have suggested that bone-lineage cells play 
a prominent role after BM injury. For instance, studies have demonstrated that transplanted 
HSPCs localize near the endosteal surface and osteolineage cells of irradiated mice (Lo 
Celso et al., 2009; Dominici et al., 2009; Jiang et al., 2009). Irradiation was associated with 
a reversible expansion of N-cadherin+ osteoblasts and concomitant CXCL12 expression 
(Dominici et al., 2009). These findings were in line with previous work that demonstrated 
that CXCL12 levels were increased after conditioning with DNA-damage agents (ionizing 
irradiation, cyclophosphamide, and 5-fluorouracil) (Ponomaryov et al., 2000). This is 
especially clinically relevant in the context of HSPC recovery after BM transplantation, which 
is preceded by conditioning regimens consisting of chemo/radiotherapy. 
Recent work has suggested that the subset of osteoblasts expressing N-cadherin can 
normally maintain HSC quiescence via non-canonical WNT signaling and after 5-FU challenge 
this signaling becomes attenuated and HSCs subsequently enter cell cycle (Sugimura et al., 
2012). Furthermore, single-cell analysis of osteoblasts from irradiated mice in direct contact 
with transplanted HSCs lead to the discovery of 3 novel HSPC regulatory factors: Embigin, 
IL-18 and angiogenin (Silberstein et al., 2016). Remarkably, angiogenin was found to 
regulate hematopoietic recovery after myeoablation by specifically promoting proliferation 
of committed progenitors, while inducing quiescence in HSCs (Goncalves et al., 2016). 
More recently, it was reported that dickkopf-1 (DKK1) released by osteoprogenitors could 
promote HSC reconstitution following irradiation by suppressing mitochondrial ROS levels 
and senescence (Himburg et al., 2017). 
Together these studies indicate that bone-lining/osteoprogenitor cells take on a prominent 
role in hematopoietic recovery after chemoradiotherapeutic insult. 
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Perivascular stromal cells 
The group of Dr. Paul Frenette was one of the first to describe the role of BMSCs upon 
regeneration by challenging Nes-GFP mice with 5-FU (Kunisaki et al., 2013). Kunisaki et 
al observed that the Nes-GFPbright cells were relatively quiescent compared to sinusoid-
associated Nes-GFPdim cells, and were subsequently also more chemoresistant upon 5-FU 
challenge. Intriguingly, the proportion of HSCs near Nes-GFPbright cells was initially increased 
after 5-FU treatment, and as regeneration progressed this proportion steadily decreased. 
The authors proposed that Nes-GFPbright cells might somehow shield HSCs from genotoxic 
insult by mediating HSC quiescence in a protective milieu, but the direct role of Nes-GFPbright 
cells or protective signals involved remains unclear.
The role of LepR-expressing BMSCs is more clear and has been recently described by multiple 
groups (Himburg et al., 2018; Zhou et al., 2017). The Morrison laboratory reported that 
SCF derived from cells marked by LepR-cre mediated hematopoietic regeneration after HSC 
transplantation in irradiated mice, as well as, in mice treated with 5-FU (Zhou et al., 2017). 
Notably, Zhou et al observed that LepR+ cells actually declined after chemo/radiotherapy 
and that SCF derived from adipocytes, presumably descendants of LepR+ cells (95% of the 
BM adipocytes were previously shown to be marked Lepr-Cre after irradiation), promoted 
hematopoietic regeneration. In addition, pleiotrophin (PTN), a novel HSPC regulatory 
factor, was identified in BM cells marked by LepR-cre and was suggested to mediate acute 
hematologic recovery and survival following irradiation (Himburg et al., 2018). 
Collectively these studies suggest that BMSC niche cells respond differently to cytotoxic 
challenge. While Nestin-GFPbright cells may be relatively chemoresistant and are associated 
with a subset of quiescent HSCs, their exact role in BM regeneration is not well described. 
LepR+ cells on the other hand seem to be more sensitive to chemoradiotherpeutic stress, 
but together with their descendants mediate hematopoietic recovery by secreting SCF and 
PTN. 
Nerve cells
Impaired adrenergic signaling in 5-FU treated mice resulted in reduced number of Nestin-
GFP+, as well as, endothelial cells and delayed hematopoietic recovery (Lucas et al., 2013). 
These findings imply that the SNS indirectly plays a role in BM regeneration by ensuring 
survival of other HSC niche components after chemotherapy. Interestingly, while the number 
of sympathetic fibers was unaltered after IR or 5FU treatment, peripheral nerve damage did 
occur in mice that received cisplatin, indicating that the response of HSC niche cells depends 
on the type of cytotoxic stressor. 
Megakaryocytes
In response to chemotherapeutic stress megakaryocytes were shown to up-regulate 
fibroblast growth factor (FGF1) to promote HSC expansion (Zhao et al., 2014). Furthermore, 
Chapter 1
21
megakaryocytes accumulate in the BM after cytotoxic stress (Hérault et al., 2017; Kopp et 
al., 2005) and megakaryocyte-derived cytokines were previously implicated as a possible 
mediator of the transient osteoblast expansion after irradiation (Dominici et al., 2009).
Conclusion
Taken together, emerging evidence from mice studies indicate that the HSC niche is 
not limited to a single cell type or anatomical location in BM. It has been proposed that 
there are multiple HSC niches situated in BM, perhaps reflecting (or contributing to?) the 
heterogeneity within the HSC pool (Haas et al., 2018). Individual niche components may have 
a specific contribution to HSC regulation, but most likely there is a complex interdependency 
and crosstalk between the different niches that enable fine-tuned regulation of the HSC 
pool under specific circumstances. In the following section, the specialized role of BM blood 
vessels will be discussed.
1.2 The role of endothelial cells in BM regeneration 
1.2.1 General
Endothelial cells (ECs), collectively termed endothelium, form a monolayer of cells that 
constitute the inner-lining of blood vessels and are most commonly known for facilitating 
blood flow and enabling exchange of nutrients and waste products. ECs are also widely 
recognized for their role in regulating vascular tone, blood clotting, and migration of 
hematopoietic cells. However, these cells perform other critical physiological tasks as 
well – signals from ECs guide the development, maintenance, and regeneration of their 
surrounding tissue. This has been shown to be especially true for BM physiology, and by 
extension, BM hematopoiesis. 
ECs have been shown to play a critical role during endochondral ossification, which is 
required for the formation of long bones and subsequent BM (Chan et al., 2009). Invading 
blood vessels are attracted to the cartilage template of bone by VEGF from hypertrophic 
chondrocytes (Gerber et al., 1999), and together with the latter, as well as, with osteoblasts 
and osteoclasts, will coordinate the development of bone. It is thought that during this 
process ECs express factors (angiocrine factors) that support osteogenesis. The expression 
of EC-derived osteogenic factors has been reported for specific endosteal blood vessels 
recently characterized in (postnatal) mice (Kusumbe et al., 2014). 
1.2.2 Endothelial cells
The importance of BM ECs for hematopoiesis first emerged in studies that focused on 
hematopoietic recovery following chemo/radiotherapy. The group of Dr. Shahin Rafii 
revealed that chemo/radiotherapy can severely disrupt the sinusoidal network, with the 
extent of damage depending on the type and magnitude of the cytotoxic agent used (Hooper 
et al., 2009; Kopp et al., 2005). Importantly, blocking regeneration of sinusoidal vessels after 
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irradiation by inhibiting VEGFR2 signaling impaired engraftment and reconstitution of HSPCs. 
In line with these findings was the observation that targeted deletion of pro-apoptotic genes 
Bak and Bax in endothelium (using either Tie2-Cre or VEcadherin-Cre mice) preserved the 
integrity of BM vasculature following lethal irradiation, which was associated with improved 
survival of mice (Doan et al., 2013a). These studies indicate that BM ECs might mediate 
HSPC reconstitution after myelosuppresive injury, but the precise mechanisms involved 
were unclear. 
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Figure 3. Regeneration-associated paracrine factors in the bone marrow (BM) vascular niche. Adapted from 
(Sasine et al., 2017). A schematic diagram of a BM blood vessel aligned with perivascular stromal cells in longitudinal 
view and representation of several paracrine factors that are secreted by BM endothelial cells and perivascular 
cells. Abbreviations: CXCL12, C-X-C chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4; EGF, epidermal 
growth factor; EGFR, epidermal growth factor receptor; HSC, hematopoietic stem cell; Jag1, Jagged-1; Jag2, 
Jagged-2; PTN, pleiotrophin; PTP-z, protein receptor tyrosine phosphatase-z; SCF, stem cell factor.
1.2.3 Endothelial cell-derived instructive (angiocrine) factors
Follow-up work revealed that BM ECs can mediate hematopoietic recovery following injury 
in a perfusion-independent manner (Figure 3). Butler et al demonstrated that inhibition 
of VEGFR2 signaling diminished endothelial expression of Notch ligands, Jagged1 and 
Jagged2, indicating that BM ECs may mediate the reconstitution of hematopoiesis by 
expressing HSPC-instructive factors (Butler et al., 2010). Indeed, it was later suggested by 
specifically disrupting Jagged1 and Jagged2 expression in ECs (using VEcadherin-Cre mice) 
that both Notch ligands can contribute to hematopoietic recovery after myelosuppressive 
injury (Guo et al., 2017; Poulos et al., 2013). Subsequently, other studies have identified 
additional angiocrine factors that may regulate HSPC recovery by mediating cell-to-cell or 
cell-extracellular matrix interactions, such as sinusoidal E-selectin (Winkler et al., 2012) and 
extracellular matrix protein developmental endothelial locus (Del)-1 (Mitroulis et al., 2017).
The team of Dr. John Chute reported that paracrine factors released by BM ECs can also 
mediate HSPC regeneration following myelosuppression. These include epidermal growth 
factor (EGF) (Doan et al., 2013b) and PTN (Himburg et al., 2010, 2018), with EGF preventing 
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radiation-induced apoptosis of HSCs, while PTN was associated with HSC expansion via 
activation of the RAS pathway (Himburg et al., 2014). Of note, it has been demonstrated 
that during steady-state conditions BM ECs also release CXCL12 and SCF, and abrogating 
CXCL12 or SCF expression in BM ECs lead to decreased HSC number (Ding and Morrison, 
2013; Ding et al., 2012; Greenbaum et al., 2013). The effects on HSPC regeneration following 
injury were not explored, but a previous report did describe that 5FU treated mice had a 
dramatic increase in SCF expression by sinusoidal ECs (Kimura et al., 2011). These studies 
indicate that ECs express instructive factors that may be involved in both HSC maintenance 
and regeneration. 
1.2.4 Crosstalk with other niche cells
Other niche cells can indirectly regulate hematopoietic recovery via BM ECs. DKK1 released 
by osteoprogenitors induced upregulation of EGF expression by BM ECs, which contributed 
to hematopoietic recovery following irradiation (Himburg et al., 2017). In addition, BM 
granulocytes were recently reported to promote EC survival and vessel growth following 
irradiation by delivering tumor necrosis factor-alpha (TNFα) to regenerative vasculature, 
which resulted in improved hematopoietic engraftment (Bowers et al., 2018). Also, as 
previously mentioned, the SNS has been suggested to mediate EC survival following 
chemotherapy. 
1.2.5 Specialized endothelium 
It has recently become clear that BM blood vessels are very heterogeneous. Besides 
structure and morphology, ECs of BM blood vessels differ in respect to their sensitivity to 
cytotoxic stress, expression of angiocrine factors, and their associated function.
For example, the endosteal capillaries that connect arterioles with sinusoids have been 
attributed with a number of specific characteristics (Kusumbe et al., 2014; Ramasamy et 
al., 2014) (Figure 2B). Endosteal capillaries, also termed Type H capillaries due to their 
high expression of CD31 and endomucin, were reported to be relatively radioresistant 
compared to sinusoidal ECs, and intriguingly, were suggested to couple BM angiogenesis 
and osteogenesis in a Notch-dependent manner by angiocrine release of Noggin. These 
endosteal capillaries were also tightly associated with perivascular osteoprogenitors marked 
by Osterix expression. Remarkably, activated Notch signaling in BM ECs also lead to HSC 
expansion (Kusumbe et al., 2016). 
Another study demonstrated that some non-sinusoidal BM ECs expressed thrombomodulin 
and maintained the retention of a small subset of LT-HSCs (marked by EPCR expression) 
in the BM by inhibiting NO production (Gur-Cohen et al., 2015). Subsequent work by the 
same lab indicated that due to leaky nature of sinusoidal ECs, HSCs exposed to plasma 
components exhibit increased ROS and are more active, while less permeable arterial ECs 
maintain lower levels of ROS and thereby confer quiescence to HSCs (Itkin et al., 2016). 
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Further supporting the notion that sinusoidal and arterial ECs exhibit specific roles was a 
very recent report that indicated that arterial ECs are the main source of endothelial SCF, 
which regulated HSC number under steady-state conditions, as well as, HSPC reconstitution 
after 5-FU challenge (Xu et al., 2018). 
Taken together these studies indicate that ECs are important and versatile. In addition to 
their conventional function, ECs are needed for HSC maintenance and regeneration, and 
can mediate these functions in a perfusion-independent manner by expressing angiocrine 
factors. Not only do they affect HSPCs, but they can also couple angiogenesis and 
osteogenesis by secreting osteogenic factors. 
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Figure 4. Plasticity of endothelium. 
a.  Adapted from (Kauts et al., 2016). Hemogenic endothelium gives rise to intra-aortic hematopoietic clusters that 
contain hematopoietic stem cells (HSCs) at embryonic day 10.5 (E10.5). 
b.  Hypothetical model of endothelium giving rise to mesenchymal multipotent stromal cells (MSCs) capable of self-
renewal and differentiating into multiple skeletal lineages.
 
1.3 Plasticity of endothelial cells
1.3.1 Endothelial-to-Hematopoietic transition and Endothelial-to-Mesenchymal 
transition
The intimate relationship between ECs and HSCs is not surprising considering that definitive 
HSCs arise from ECs during embryogenesis. In mice at embryonic day (E) 10.5, specialized 
ECs in the aorta-gonad-mesonephros (AGM) region, called hemogenic endothelium, start 
giving rise to hematopoietic clusters by undergoing endothelial to hematopoietic transition 
(EHT) (Figure 4A). These hematopoietic clusters contain the HSCs that will give a life-long 
supply of blood cells and components (de Bruijn et al., 2002). Of note, the actual number 
of HSCs in these clusters is very low (2/700) (Yokomizo and Dzierzak, 2010), indicating that 
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in addition to EHT, HSC-precursors need to undergo a molecular program that specifies HSC 
fate.  The AGM itself is thought to originate from embryonic mesoderm, specifically the 
splanchnopleural mesoderm (Rosselló Castillo et al., 2013). Ultimately, the generated HSCs 
migrate to fetal liver where they will undergo massive expansion prior to colonizing the BM 
of fetal long bones.
In addition to giving rise to HSPCs at the AGM, ECs of other tissues can directly contribute 
to organogenesis by transforming into other cell types. For example, ECs of the embryonic 
heart (endothelial endocardial cells) can give rise to mesenchymal cells necessary for proper 
heart development by undergoing endothelial to mesenchymal transition (EndMT). EndMT 
is required for the generation of the atrioventricular valves, as well as, the formation of 
endocardial cushion (Liebner et al., 2004) and a substantial portion of the cardiac pericytes 
and vascular smooth muscle cells (Chen et al., 2016). Intriguingly, endothelial endocardium-
derived cells have been reported to give rise to osteogenic and adipogenic cells (Pu et al., 
2016; Wylie-Sears et al., 2011). This remarkable plasticity of endothelium was also observed 
in ECs of human skeletal muscle that were reported to be able to differentiate into myogenic, 
osteogenic and chondrogenic cells in culture (Zheng et al., 2007) (Figure 4B). 
1.4 Scope and outline of this thesis
Recent studies in mice have led to the recognition of BM ECs as critical HSC niche 
components that can mediate hematologic recovery after injury. Furthermore, these studies 
also identified specialized subsets of endothelium that not only regulate the hematopoietic 
system, but also couple osteogenesis and angiogenesis. Importantly, insights into the 
molecular programs underlying the specialized function of these endothelial subsets have 
enabled targeted interventions in mice, such as pharmacologic manipulation that enhanced 
bone formation or administration of recombinant proteins that promoted hematologic 
recovery after injury. However, the relevance of these findings for human biology remains 
relatively unknown. In particular, studies in humans that have attempted to unravel the 
specific contributions of BM ECs to hematologic recovery are scarce. To identify potential 
targets for therapeutic modulation to accelerate hematologic recovery in humans, a better 
understanding of the relevant cellular constituents and molecular pathways underlying 
hematologic recovery is needed. 
In this thesis, we aimed to better define cellular and molecular events that occur in the 
human bone marrow during (re)generation, in order to identify novel cellular programs and 
mechanisms that might be exploitable for therapeutic modulation. 
To this end, we defined two distinct (patho)physiologic conditions associated with BM 
(re)generation, requiring coordinated activation of osteogenesis, angiogenesis, and 
hematopoiesis, namely (1) regeneration after chemotherapeutically-induced injury and (2) 
bone marrow generation in human fetal development upon migration from hematopoiesis 
from the fetal liver to the bone at week 15–20 post gestation.
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In chapter 2, we characterized human BM ECs associated with BM (re)generation in these 
conditions by flow-cytometry. Massive parallel sequencing was employed in EC subsets to 
identify candidate angiocrine factors that might drive hematologic recovery. This led to the 
identification of IL-33 which was subsequently functionally interrogated for its regenerative 
potential in bone and marrow. In chapter 3, we build upon the observation in chapter 2 that 
BM ECs exist that co-express mesenchymal markers, suggesting the possibility that specific 
BM ECs might contribute to BM regeneration by giving rise to mesenchymal progenitors (via 
EndMT). This notion is tested by extensive experimentation in both human cells and mice, 
leading to the postulation of EndMT as novel concept in bone marrow (re)generation and 
the de novo generation of MSCs in the mammalian BM. IL-33 is subsequently identified as 
a driver of this process. 
As immune cells have also been implicated to regulate HSPC behavior, we dissected the 
BM lymphoid composition of the AML patients recovering (from remission induction 
chemotherapy) to determine whether specific immune subsets are associated with 
hematologic recovery in chapter 4. Finally, in chapter 5 the findings in this thesis are 
summarized and their relevance for the field of BM regeneration, including future 
perspectives, are discussed. 
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SUMMARY
Bone marrow formation requires an orchestrated interplay between osteogenesis, 
angiogenesis and hematopoiesis that is thought to be mediated by endothelial cells. The 
nature of the endothelial cells and the molecular mechanisms underlying these events 
remain unclear in humans.  Here, we identify a subset of endoglin-expressing, endothelial 
cells enriched in human bone marrow during fetal ontogeny and upon regeneration after 
chemotherapeutic injury. Comprehensive transcriptional characterization by massive parallel 
RNA sequencing of these cells reveals a phenotypic and molecular similarity to murine H 
endothelium, and activation of angiocrine factors implicated in hematopoiesis, osteogenesis 
and angiogenesis. IL-33 was significantly overexpressed in these endothelial cells and 
promoted the expansion of distinct subsets of hematopoietic precursor cells, endothelial 
cells, as well as osteogenic differentiation. The identification and molecular characterization 
of these human regeneration-associated endothelial cells is thus anticipated to instruct the 
discovery of angiocrine factors driving bone marrow formation and recovery after injury.
KEYWORDS
Endothelial, bone marrow, niche, regeneration, development, hematopoietic stem/
progenitor cell, bone formation, interleukin-33
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INTRODUCTION
Endothelial cells (ECs) govern tissue development and regeneration by signaling molecules 
on their cell surface and the release of factors such as cytokines and extracellular matrix 
proteins. This angiocrine function of the endothelium drives tissue development and 
regeneration in multiple organs. 
In the hematopoietic system, studies in mice have revealed pivotal contributions of 
ECs to the formation and regeneration of bone and bone marrow (BM) (Hooper et al., 
2009; Ramasamy et al., 2016). Coordinated activation of osteogenesis, angiogenesis 
and hematopoiesis is required for BM regeneration after tissue injury (Rafii et al., 2016; 
Ramasamy et al., 2015) induced by irradiation or chemotherapy. ECs support the proper 
regeneration of the hematopoietic system following myeloablation (Butler et al., 2010; 
Hooper et al., 2009; Kobayashi et al., 2010). Engraftment and repopulation of hematopoietic 
stem and progenitor cells (HSPCs) in mice is dependent on regeneration of sinusoid ECs 
which are vulnerable to toxic injury (Hooper et al., 2009). Sinusoid regeneration is mediated 
through vascular endothelial growth factor receptor 2 (VEGFR2) signaling, blockage of which 
resulted in delayed reconstitution of peripheral blood values in irradiated mice (Hooper et 
al., 2009).
ECs do not seem to be created equally in their ability to drive or contribute to bone and 
hematopoietic development and regeneration. Recent studies in mice have identified 
a specialized endothelial subset that controls HSPC number in addition to coupling 
angiogenesis and osteogenesis (Kusumbe et al., 2016, 2014; Ramasamy et al., 2014). This 
endothelial subtype, dubbed type H endothelium for its high expression of endomucin and 
CD31, is enriched in the bone metaphysis at the endosteal surface where it is adjacent to 
osteoprogenitor cells and gives rise to sinusoidal endothelial vessels. Importantly, insight 
into the molecular programs underlying the capacity of this endothelial subtype to drive 
angiogenesis and osteogenesis enabled its pharmacologic manipulation in mice resulting in 
increased bone formation (Kusumbe et al., 2014; Ramasamy et al., 2015).
Taken together, various studies indicate that specified EC-derived signals can orchestrate 
complex multicellular network interactions in the mammalian marrow driving bone 
formation and regeneration under stress conditions. These findings in murine models open 
the perspective of EC-instructed strategies to regenerate bone and marrow in humans, both 
in degenerative conditions as well as after injury such as chemotherapy and irradiation. 
Translation of these important findings to human regenerative medicine, however, will be 
critically dependent on our ability to identify and interrogate molecularly equivalent human 
ECs driving ontogeny and regeneration. 
Here, we describe the identification of a human EC subtype that is strongly associated with 
human fetal BM development and regeneration after chemotherapeutic injury. This EC 
displays striking immunophenotypic and molecular commonalities with type H endothelium 
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in mice, including transcriptional activation of programs and angiocrine factors previously 
related to BM recovery in mice. Interleukin 33 (IL-33 is) identified as a putative regenerative 
factor facilitating hematopoietic expansion and bone mineralization ex vivo, thus supporting 
the notion that the transcriptome of this human EC may serve as an important resource 
instructing discovery as well as validating the relevance of findings in murine models to 
human regenerative medicine. 
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RESULTS
Identification of endoglin (CD105)-expressing ECs associated with bone marrow 
regeneration after chemotherapeutic injury
To identify niche cells potentially implicated in regeneration of the hematopoietic system 
in humans, we interrogated the composition of the hematopoietic niche upon recovery 
after chemotherapeutic injury. Chemotherapeutic exposure causes damage to endothelial, 
hematopoietic and osteolineage cells within the BM (Hooper et al., 2009; Kopp et al., 2009; 
Lerner and Harrison, 1990; Xian et al., 2006) resulting in a prolonged neutropenia associated 
with considerable morbidity and mortality in humans. Flow-cytometric assessment of the 
niche (7AAD-CD45-CD235a-, Figure 1A) composition in the regenerating BM of acute myeloid 
leukemia (AML) patients (see ‘experimental procedures’) revealed an unaltered frequency 
of ECs (CD31+CD9+) (Barreiro et al., 2005) in comparison to marrow under homeostatic 
conditions (healthy donors) (22.1% ± 2.24 vs 31.57% ± 9.66; p=0.15 by unpaired student 
t-test) (Figure 1A, B). To identify putative immuno-markers of EC subtypes emerging during 
regeneration, we performed massive parallel sequencing (RNAseq) of the fluorescence-
activated cell sorting (FACS)-purified endothelial compartment (CD31+CD9+) (Figure 1A). 903 
transcripts were found to be significantly differentially expressed in ECs in the regenerative 
marrow in comparison to ECs from normal, steady-state, marrow (GLM LRT Edge R; FDR 
<0.05). The top 200 overexpressed transcripts contained 16 genes encoding for cluster of 
differentiation (CD) molecules, among which CD105 (endoglin) (Table S1), a co-receptor for 
transforming growth factor β (TGFβ) promoting angiogenesis (Cheifetz et al., 1992; Duff et 
al., 2003) (Miller et al., 1999) and previously associated with tissue injury (Wang et al., 1995). 
CD105 protein levels, assessed by FACS analysis (Figure 1C), identified a distinct subset of 
CD105-expressing ECs, strongly enriched in the regenerative marrow compared to normal 
BM (10.81% ± 2.14 vs 0.48% ± 0.24 of CD31+CD9+; p=0.043) (Figure 1D). The presence of this 
endoglin-expressing subset was temporally restricted, as it was (virtually) absent in AML 
patients at diagnosis (0% ± 0 of CD31+CD9+) or after full recovery of peripheral blood values 
(in complete remission) (1.27% ± 0.66 of CD31+CD9+) (Figure 1E). 
Endoglin-expressing ECs are enriched in the mouse bone marrow after chemo-
therapeutic myeloablation 
To confirm our observation that the CD105 expressing subset of endothelial cells is enriched 
during bone marrow regeneration and establish a broader relevance for mammalian biology, 
we next translated our observations to an experimental setting in which we exposed C57BL/6 
wild-type mice to a myeloablative dose of the chemotherapeutic agent 5-fluorouracil (5FU) 
or PBS (vehicle control). The endoglin-expressing subset constituted a rare subpopulation 
of endothelial (CD31+CD9+) cells in the steady-state adult BM niche (0.05% ± 0.02 of CD45-
Ter119- cells) and in the collagenased bone niche (0.42% ± 0.12 of CD45-Ter119- cells) (Figure 
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2A, B and S1A, B). This fraction increased significantly after administration of 5FU in the 
BM (0.65% ± 0.15 of CD45-Ter119- cells, fold-change (FC) increase of 13.6 ± 3.2, p=0.026) 
and collagenased bone (8.18% ± 1.43 of CD45-Ter119- cells, FC increase of 19.6 ± 3.4, 
p=0.007) (Figure 2A, B and S1A, B), confirming a relative increase of this specific subset in 
the regenerative phase after myeloablation. Of note, the absolute number of CD31+CD105+ 
ECs in the bone marrow did not increase after exposure to 5FU (Figure 2C), suggesting that 
selection of these cells under chemotherapeutic pressure (rather than absolute expansion) 
may be implicated.
Endoglin-expressing ECs are enriched in the human bone marrow during fetal 
development
The temporally restricted enrichment of CD105-expressing ECs during recovery after 
chemotherapeutic injury suggests that this cell type could potentially be implicated 
in regeneration and hematopoietic niche formation. To corroborate this notion, we 
sought to define other conditions in human biology where angiogenesis, osteogenesis 
and hematopoiesis are synergistically activated. In human fetal bone development, 
hematopoiesis shifts from the fetal liver to the bones starting from week 10 after 
gestation. During this process angiogenesis, osteogenesis and hematopoiesis are tightly 
coupled to allow coordinated bone and hematopoietic development (Coşkun et al., 2014; 
Jagannathan-Bogdan and Zon, 2013; Medvinsky et al., 2011). Invasion of blood vessels 
into the mesenchymal condensate is crucial for the coordinated activity of chondrocytes, 
osteoblasts and each of these cell types stands in spatial and molecular interaction with ECs 
(Maes, 2013; Salazar et al., 2016).
Flow cytometric dissection of the endothelial composition of fetal bone marrow at 
gestational week 15-20 revealed a striking predominance of CD105-expressing cells within 
the endothelial compartment (62.8% ± 5.9 of CD31+CD9+) (Figure 3A, B). Massive parallel 
sequencing of these cells confirmed overexpression of genes encoding CD markers identified 
in the endothelial cells in regenerating bone marrow (Figure S2A), supporting the notion 
that the enrichment of these transcripts in ECs in the regenerative marrow is caused by 
overexpression in the subset of CD105+ ECs.
The frequency of CD105-expressing ECs within the endothelial compartment was even higher 
when examining collagenased fetal bone fractions (average 82.65% ± 2.5 of CD31+CD9+) 
(Figure 3A, B), suggesting that this endothelial subpopulation might preferentially localize 
to the endosteal surface of fetal long bones. In line with this, CD105-expressing ECs were 
identified, albeit at considerably lower frequency, in collagenased bone fractions of human 
adult postnatal bone (average 25.9% ± 5.0 of CD31+CD9+) (Figure 3A,B).
To provide anatomical context for this CD31+CD105+ EC subset, we performed in situ 
immunohistochemistry and immunofluorescence on fetal femurs and core hip bone biopsies 
obtained from adults. CD31+CD105+ EC were observed in the trabecular bone area of the 
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metaphysis of fetal femurs (Figure 3C and S3A, B) at a significant higher frequency than in 
the trabecular bone of adult bone marrow. The majority of vascular structures in both fetal 
and adult human bone were lined with CD31-CD105+ endothelial cells, previously shown to 
be sinusoid endothelial cells. CD31+CD105- cells were present sporadically in adult bone. 
Collectively, these findings identify a human endothelial subtype that is enriched in 
collagenased bone fractions, prevalent during human fetal bone development, declines in 
frequency upon aging and emerges, in a temporally restricted fashion, in the BM during 
regeneration after chemotherapeutic injury. Henceforward, we will refer to this EC type as 
‘human regeneration-associated EC’ or hREC.
hRECs share immunophenotypic and molecular similarities with murine type H 
endothelium and express key regulators of angiogenesis and osteogenesis
Interestingly, similarities exist between hRECs and the recently described specialized 
endothelium coordinating osteo- and angiogenesis in mice, termed type H endothelium 
(Kusumbe et al., 2016, 2014; Ramasamy et al., 2014). These include the enrichment at the 
bone surface, reduced frequencies upon aging and an increase in frequency upon genotoxic 
stress, suggesting that hRECs may reflect human equivalents of mouse ‘type H endothelium’. 
To further investigate this, differentially expressed transcripts in CD31+CD9+CD105+ hRECs 
isolated from human fetal bone (in comparison to steady-state postnatal CD31+CD9+CD105- 
cells) were related to genes reported to be overexpressed in H-endothelium. This confirmed 
elevated expression of many transcripts previously reported to be enriched in type H 
endothelium, including genes encoding the signature markers CD31 (PECAM1) and mucin-
like sialoglycoprotein endomucin (EMCN) (Figure 4A) and vessel guidance molecules 
(Ramasamy et al., 2014) (Figure 4B). Most of these genes were similarly enriched in the 
CD31+CD9+ fraction of regenerative BM (Figure 4A, B) (the limited number of CD105+ 
precluded RNA-sequencing of this specific subset). In total, 3718 genes were differentially 
expressed (GLM LRT Edge R; FDR < 0.05) in fetal bone hRECs in comparison to steady-state 
postnatal BM ECs. Among the overexpressed genes were HSPC niche factors (Figure 4C) and 
known angiocrine anabolic regulators of osteogenesis and angiogenesis (Figure 4D), further 
suggesting that hREC might be involved in hematopoietic niche formation. 
Next, transcriptional programs and signatures were interrogated in hRECs using gene set 
enrichment analysis (GSEA) (Subramanian et al., 2005). Activated Notch signaling and 
stabilization of HIF1a have been identified in H endothelium as key promotors of the 
formation of type H capillaries and release of osteogenic factors that enhance osteogenesis 
(Kusumbe et al., 2014; Ramasamy et al., 2014). In line with this, key NOTCH regulators such 
as Jagged-1, DLL4, NOTCH 1 and NOTCH4 (receptors of DLL4) were upregulated in fetal 
hRECs (Figure 4E), reflected in activation of downstream transcriptional NOTCH signaling, 
as demonstrated by GSEA (Figure 4F). Similarly, gene sets related to the HIF1a pathway 
were enriched in fetal hREC according to GSEA (Figure S2B). Other relevant molecular 
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signatures that were identified to be significantly enriched in hRECs include ‘angiogenesis’- 
and ‘stemness’- signatures, among which VEGF and WNT-signaling (Figure S2C). Together, 
the data indicate that hRECs share immunophenotypic and molecular commonalities with 
murine type H ECs and have a transcriptional wiring that may be congruent with the view that 
these cells are implicated in the coupling of hematopoiesis, osteogenesis and angiogenesis 
in regeneration.
Interleukin-33 is expressed by hRECs and promotes angiogenesis, osteogenesis 
and the expansion of hematopoietic precursor cells 
We thus hypothesized that elucidation of the transcriptome of ECs related to hematopoietic 
niche formation might instruct the discovery of pathways or proteins facilitating niche 
formation. In particular, angiocrine factors may be identified that facilitate angiogenesis, 
osteogenesis and hematopoiesis. To provide proof of principle for this assumption, we 
focused our attention on genes encoding secreted factors that were both significantly 
enriched in fetal hRECs and regenerative BM ECs. In total 237 genes were significantly 
enriched, of which 34 are genes encoding known secreted factors with a strong correlation 
in levels of expression (Figure 5A). Of interest, the canonical receptors of many of these 
secreted proteins were overexpressed in fetal hRECs, (MMRN2-CLEC14A, BMP4-BMPR2, 
EFNA1-EPHA2/EPHA4/EPHA7, EDN1-EDNRB, SEMA3A-NRP1/NRP2/PLXNA2, ADM-RAMP2/
CALCRL) (Figure S2D), suggesting the possibility of autocrine signaling.
In addition to secreted factors with a known role in regulating HSPC behavior, such as 
plasminogen activator (PLAT) (Ibrahim et al., 2014) and tissue factor pathway inhibitor (TFPI) 
(Khurana et al., 2013), we found significant overexpression of interleukin-33 (IL33) in hRECs 
(Figure 5A). 
IL-33 is a pro-inflammatory cytokine and a chromatin-associated nuclear factor (Carriere 
et al., 2007). IL-33 protein expression in fetal hREC was confirmed using fluorescence 
microscopy (Figure 5B) and IL-33 was differentially overexpressed in murine CD31+CD105+ 
endothelial cells in comparison to their CD105- counterparts during regeneration (Figure 
2D, E). The inability to propagate sorted hRECs ex vivo (data not shown), precluded the 
possibility to perform co-culture blocking experiments to assess the contribution of hREC-
derived IL-33 to angiogenesis, hematopoiesis and osteogenesis. As an alternative strategy, 
we exposed relevant cell types to recombinant human IL-33 (rhIL-33). 
Hematopoiesis
To test if IL-33 facilitates human hematopoiesis in vitro, we exposed cord blood (CB) CD34+ 
HSPCs to rhIL-33 or vehicle control for a week in serum-free medium containing SCF. rhIL-
33 expanded the total number of hematopoietic cells (total MNCs) (3.4-fold increase ± 
0.29; p<0.01) with a concomitant expansion of hematopoietic progenitors cells (HPCs), 
specifically immunophenotypic multipotent progenitors (MPPs) (2.5-fold increase ± 0.43; 
p<0.05) and multilymphoid progenitors (MLPs) (2.7-fold increase ± 0.15; p<0.01) (Figure 5C, 
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S4). Immunophenotypic HSC numbers were not affected by exposure to IL-33. Expansion of 
myeloid progenitor cells was confirmed in colony-forming assays (CFU-C) demonstrating an 
increase in CFU-GMs (2.27-fold increase ± 0.21; p<0.05) (Figure 5D). 
Osteogenesis
Next, we interrogated a potential role of IL-33 in bone formation. In human fetal bone 
development (endochondral ossification), vascular invasion of chondrocytes coincides with 
expansion of osteoblasts and mineralization of the matrix (Charbord et al., 1996; Ramasamy 
et al., 2016). To test the role of IL-33 in this process, the effect of rhIL-33 on the osteogenic 
differentiation of human BM-derived stromal cells (BMDSCs) was assessed. Addition of rhIL-
33 to osteogenic induction medium accelerated terminal differentiation of BMDSCs towards 
matrix-depositing osteoblasts as suggested by Alizarin red-staining (Figure 6A), indicating 
increased calcific matrix deposition. To confirm this finding, we performed colorimetric 
assessment of calcium deposition, demonstrating a striking 3.61-fold ± 0.63 (p<0.02) 
increase in calcium deposition of IL-33-exposed BMDSCs in comparison to BMDSCs cultured 
in osteogenic induction medium alone (Figure 6B). The proliferation of BMDSCs was not 
affected by rhIL-33 (Figure S5A, B), suggesting that IL-33 exerted its osteogenic effect by 
promoting osteoblastic differentiation or the secretion of matrix proteins by osteoblasts, 
rather than expanding primitive mesenchymal cells.
Angiogenesis
In line with earlier reports (Choi et al., 2009), we confirmed that IL-33 is an angiogenic factor. 
shRNA mediated-knockdown of IL-33 (Figure S5D, E) from HUVECs dramatically impaired 
their expansion in culture (Figure 6C), indicating that IL-33 promotes angiogenesis in an 
autocrine fashion. 
IL-33 promotes expansion of hematopoietic precursor cells and alters the 
architecture of the bone marrow niche in mice
We next studied the in vivo relevance of these effects of IL-33 on distinct cellular components 
of the human bone marrow. Administration of recombinant murine IL-33 (rmIL-33) compared 
to PBS control resulted in expansion of immature (Lin-) (Figure S6A) and primitive progenitor 
(LKS) hematopoietic cells, in particular the HPC-1 population (Figure 7A, B), earlier shown 
to contain restricted hematopoietic precursor cells with myeloid and lymphoid lineage 
potential (Oguro et al., 2013). Expansion of a myeloid progenitor population was confirmed 
with CFU-C assays (Figure S6B). Total BM cellularity, and Lin-Kit+Sca1- cell counts remained 
unchanged (Figure S6C). In addition, the number of granulocyte-macrophage progenitors 
(GMPs) and myeloid cells increased after IL-33 administration (Figure 7A, B, and Figure 
S6D, E), recapitulating the expansion of human hematopoietic, myeloid, precursors in 
vitro. Congruent with our findings in human hematopoietic cells, immunophenotypic HSCs 
were not numerically affected by IL-33 (Figure 7A, B). Interestingly, IL-33 also expanded 
significantly the population of Lin-Kit-Sca1+ bone marrow cells, previously shown to contain 
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early lymphoid-committed precursors with T cell, B-cell and NK cell potential (Kumar et al., 
2008) and innate lymphoid cells (Brickshawana et al., 2011). Hematopoietic changes were 
accompanied by a relative increase in CD31+CD105+ ECs as well as Lin-Ter119-CD51+Sca- cells 
(earlier shown to contain lineage committed/osteoblastic cells) (Schepers et al., 2012), albeit 
not reaching statistical significance, within the niche compartment (Figure S7A, B). 
Collectively, the in vitro and in vivo data indicate that IL-33 modulates distinct cellular 
components of the hematopoietic tissue and has the potential to facilitate angiogenesis, 
hematopoiesis and osteogenesis, supporting the view that elucidation of the transcriptome 
of hRECs may instruct the identification of modulators of these processes. 
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DISCUSSION
Injury to the hematopoietic system, caused by chemotherapy or irradiation, is a significant 
cause of morbidity and mortality in the treatment of malignant hematopoietic disease. 
Studies in mice have demonstrated a pivotal role of specific BM niche cells and secreted 
molecules in hematopoietic recovery. Translation of these findings to the clinic, however, 
is hampered, principally by insufficient understanding of the niche cells and molecular 
programs governing niche formation and hematopoietic recovery in humans. Here, by 
cellular dissection of the BM niche in humans during fetal development and regeneration 
after chemotherapeutic injury we reveal the existence of a specific EC type (hREC) 
associated with these conditions. hRECs share phenotypic and molecular similarities with 
specialized EC driving hematopoietic niche formation in mice, expressing critical regulators 
of hematopoiesis, osteogenesis and angiogenesis. The data comprises, to our knowledge, 
the first comprehensive molecular characterization of human ECs upon tissue regeneration 
after injury. 
We identified the TGF-β1 receptor endoglin (CD105) as a marker of endothelium associated 
with BM (re)generation in fetal development and after chemotherapeutic injury. Endoglin-
expressing ECs have earlier been associated with angiogenesis in tumors and inflammation 
(Kumar et al., 1996) and loss of endoglin results in defective angiogenesis in mice (Li et 
al., 1999), supporting the view that it mediates signals governing blood vessel formation. 
The data indicate that endoglin with concomitant CD31 expression marks a specific subset 
of angiogenic endothelial cells which is further supported by observations that endoglin 
expression is strongly elevated in ECs of small capillary-like vessels at tumor edges (Miller 
et al., 1999; Yoshitomi et al., 2008). Endoglin thus likely identifies a subset of endothelium 
during ontogeny and regeneration that marks an angiogenic subset, in line with observations 
in different settings. 
This subset revealed remarkable molecular congruence with EC subsets identified in murine 
studies driving bone and BM regeneration after injury. ECs in mice support the regeneration 
of the hematopoietic system following injury such as myeloablation (Butler et al., 2010; 
Hooper et al., 2009; Kobayashi et al., 2010) and in recent years several markers of specified 
endothelial subsets exerting this function as well as the underlying mechanisms have been 
revealed. Interestingly, hREC share many characteristics with the ECs described in these 
studies, including expression of the cell surface proteins Tie2/TEK (Figure S2E) (Doan et al., 
2013; Kopp et al., 2005), EMCN (Kusumbe et al., 2014; Ramasamy et al., 2014), Jagged1 and 
activation of specific signaling pathways, including NOTCH (Butler et al., 2010; Poulos et al., 
2013). Also, hRECs express many molecules previously shown to regulate HSPC behaviour 
in mice such as PLAT (Ibrahim et al., 2014), TFPI (Khurana et al., 2013), E-selectin (ESELE) 
(Figure S2E) (Winkler et al., 2012), thrombomodulin (TMBD) (Figure S2E) (Gur-Cohen et al., 
2015), tenascin C (TNC) (Figure S2E) (Nakamura-Ishizu et al., 2012). 
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In particular, hRECs displayed striking commonalities with H endothelium, a murine EC 
subtype that has recently been functionally implicated in EC-driven formation of the niche 
through activation of NOTCH and HIF1 signaling (Kusumbe et al., 2014; Ramasamy et al., 
2014). Commonalities with the now identified hRECs include enrichment at the bone surface, 
reduction in frequency upon ageing, resistance to stress conditions, expression of markers 
typical for both arterial (Ephn2b, Nestin, Nrp1, Sox17, VEGFR2), and sinusoidal vessels 
(VEGFR3, EMCN) and activation of the NOTCH and HIF1 pathways driving regeneration. 
Expression of CD105 was not addressed in the studies on H endothelium but our data 
in mice show that a rare population of endoglin expressing endothelial cells increases 
in frequency in the regenerative phase after chemotherapy, likely reflecting increased 
resistance to myeloablative stress. It is noteworthy that CD105+ ECs associated with elevated 
HIF-1a expression have been described in the BM of mice upon regeneration following 5-FU 
treatment (Nombela-Arrieta et al., 2013) making it tempting to hypothesize that these 
represent similar or overlapping cell types. 
Taken together, these immunophenotypic and molecular similarities between hRECs and 
murine endothelial subtypes implicated in hematopoietic niche formation point towards 
evolutionary conservation of these cells between mammalian species. They thus provide 
human relevance to findings in murine studies, supporting the notion that ECs are implicated 
in niche regeneration in humans. 
Providing experimental support for this view is challenging by limitations inherent to the 
study of human cells as well as the inability to propagate highly purified hRECs ex vivo, 
precluding co-culture studies. As an alternative approach, we exploited elucidation of 
their transcriptome to identify candidate factors driving EC-driven formation of the 
hematopoietic niche and regeneration of HSPCs. We identified IL-33, a cytokine typically 
associated with innate immunity and inflammation (Cayrol and Girard, 2014) as a candidate 
factor. IL33 was overexpressed in human hRECs and expression was increased in murine 
CD31+CD105+ ECs upon exposure to 5FU. Hematopoietic niche regenerating properties 
of IL33 was demonstrated by its ex vivo capacity to facilitate hematopoiesis (increased 
numbers of HPCs), osteogenesis (accelerating terminal differentiation of BMDSCs towards 
matrix-depositing osteoblasts), and angiogenesis (expansion of HUVECs). The data follow 
recent reports demonstrating IL-33 to predominantly act as an “alarmin”, released by cells 
undergoing necrosis after tissue damage or active secretion (Kakkar et al., 2012; Lee et 
al., 2015) and playing anabolic roles in angiogenesis (Choi et al., 2009; Shan et al., 2016) 
and osteogenesis (Saleh et al., 2011). Our finding that human recombinant IL-33 increased 
the numbers of HPCs ex vivo seems congruent with recent observations in mice where 
administration of IL-33 promoted myelopoiesis (Kim et al., 2014). Of considerable interest, 
rhIL-33 in our experiments expanded both immunophenotypic MLPs and MPPs, in line with 
observations in experiments in mice where expansion of splenic lymphoid progenitors after 
IL-33 administration resulted in enhanced defense against opportunistic infection (Kim et 
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al., 2014). Formal demonstration that secretion by a defined subset of ECs is required for 
the regenerative actions of IL-33 will have to await in vivo targeted deletion experiments, 
as it is currently challenging to maintain this particular subset of ECs ex vivo to enable co-
culture experiments. The profound effect of IL33 knockdown on HUVEC proliferation and 
maintenance precluded use of this ex vivo system to address this question. 
The combined findings point to a unique role of IL-33 in mammalian species facilitating the 
reconstitution of both hematopoietic lineages, which may be of considerable importance 
to prepare the hematopoietic system for extra-uterine environment in ontogeny but 
also for immune reconstitution after injury, e.g. hematopoietic stem cell transplantation 
characterized by long-term lymphocyte depletion and ensuing opportunistic infections. 
The exact molecular mechanisms by which IL-33 exerts these effects (either direct or 
indirect) remain to be fully elucidated. IL-33 expression in HUVECs has been associated 
with a quiescent cellular state (Küchler et al., 2008) and, although we did not examine the 
cell cycle status of CD31+CD105+, IL-33 high hRECs, this might help explain the notion that 
they may be relatively resistant to chemotherapeutic myeloablation. We can speculate that 
quiescent CD31+CD105+, IL-33 high hRECs survive chemotherapy and are ‘activated’ to release 
IL-33 as an anabolic hematopoietic factor. In this context it is noteworthy that hRECs display 
transcriptional activation of DLL4 and the Notch pathway, earlier shown to be an important 
driver of IL-33 expression (Sundlisæter et al., 2012). 
Regardless the underlying molecular mechanisms of IL-33 expression, the data support 
the notion that elucidation of the transcriptome of hRECs may instruct the identification of 
proteins and pathways driving niche formation after injury. It is conceivable that receptor-
ligand interactions allows targeting of these cells to drive regeneration (as previously shown 
by pharmacologic modulation of NOTCH signaling in mice (Ramasamy et al., 2014). In this 
context, it is noteworthy that transcriptional profiling of fetal hRECs revealed overexpression 
of genes encoding secreted factors as well as their receptors suggesting potential relevance 
of autocrine signaling in the biology of hRECs. Alternatively, it will be worthwhile testing the 
ability of identified secreted factors to expand human HSPC ex vivo, either direct or in co-
culture settings with mesenchymal elements. 
Collectively, the identification of human ECs associated with hematopoietic niche formation 
and elucidation of their transcriptome is anticipated to provide a valuable resource for the 
regenerative community to relate findings in animal models to human biology and to instruct 
in vivo and ex vivo approaches to foster EC-driven regeneration of the hematopoietic system 
after injury. 
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Figure 1. Identification of CD105 (endoglin)-expressing endothelial cells associated with bone marrow 
regeneration after chemotherapeutic injury 
Bone marrow (BM) obtained by aspirates upon recovery after chemotherapeutic injury (AML D17) was compared 
to normal adult BM. 
a.  Gating strategy for identification and isolation of endothelial cells (ECs). After doublet exclusion, 7AAD- 
mononuclear cells (MNCs) were gated based on low/negative CD45 and CD235a expression to identify niche 
cells. ECs were identified as CD31+CD9+ cells within the niche. 
b. Frequency of ECs within the niche in adult steady-state (n=9) and regenerative (n=48) BM. 
c. Representative FACS plots revealing the existence of a CD105-expressing endothelial subset in regeneration. 
d.  The frequency of CD105+ cells in the endothelial niche in normal BM (n=9) and during  regeneration after 
chemotherapy (n=48).
e. The frequency of CD105+ cells in the endothelial niche in BM aspirates of AML patients at diagnosis (n=4), and 
after recovery in complete remission (n=3). 
Data represent mean ± s.e.m. *p <0.05, two-tailed unpaired t-test. AML=Acute Myeloid Leukemia. BM=Bone 
marrow. D17=Day 17. CR=Complete Remission. 
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Figure 2. CD105-expressing endothelial cells are enriched in mice during regeneration after chemotherapeutic 
injury 
a.   Representative FACS plots for identification of murine BM ECs. After doublet exclusion, 7AAD- mononuclear 
cells (MNCs) were gated based on low/negative CD45/ Ter119 expression to select for BM niche cells. BM ECs 
were identified by CD31 and CD105 expression. 
b.   Frequency of CD105+ ECs within the murine BM niche during S.S (n=3 mice) and upon recovery after 5-FU (n=5 
mice). 
c.   Numbers of CD105+ BM ECs during S.S (n=3) and after 5-FU treatment (n=5). 
d, e.  CD105+ BM ECs differentially express IL-33 upon injury. (d) Representative FACS plots. (e) IL-33 expression in 
CD105+ BM ECs and CD105- BM ECs in S.S (n=3) and after 5-FU treatment (n=5). 
Data represent mean ± s.e.m. *p <0.05, two-tailed unpaired t-test. S.S=Steady-state. 5-FU=5-fluorouracil. 
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Figure 3. CD105-expressing endothelial cells are enriched in fetal development and collagenized bone fractions 
a. Representative FACS plots identifying CD105-expressing ECs in fetal BM, fetal bone and adult bone.
b.  Frequency of CD105+ cells in the endothelial compartment in healthy adult BM aspirates (n=9), fetal BM (n=15), 
fetal bone (n=21), and adult bone (n=9). Data represent mean ± s.e.m. **p <0.01, ***p <0.001, one-way ANOVA 
(p< 0.0001) followed by Bonferroni’s Multiple Comparison Test. BM= Bone marrow.
c.  In situ immunofluorescence demonstrating the existence of capillary structures in the trabecular area of fetal 
long bone comprised of CD31+CD105+ endothelial cells (arrowheads). Sinusoid structures are CD31loCD105+. In 
human adult  BM, the majority of CD31+ endothelial cells lacks CD105 expression (asterisks). Area within the 
dotted line in the adult BM represent bone tissue. 20x magnification. White scale bar represents 100 µm.
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Figure 4. hRECs express transcriptional programs defining niche-forming endothelial cells in mice 
Transcriptomes of hRECS isolated from human fetal bone (CD45-CD235-CD31+CD9+CD105+)(n=3) and regenerative 
bone marrow (CD45-CD235-CD31+CD9+)(n=3) were compared to postnatal steady-state BM ECs (CD45-CD235-
CD31+CD9+)(n=7). 
a,b.  Expression of genes previously reported to be overexpressed in murine type H endothelial cells (Itkin et al., 
2016; Kusumbe et al., 2016, 2014; Ramasamy et al., 2014). Note, Sca-1 has no known human homolog (Holmes 
and Stanford, 2007). 
c.   Expression of established hematopoiesis-supporting cytokines (Broudy, 1997; Sugiyama et al., 2006; Zhang et 
al., 2006). 
d.   Expression of genes encoding anabolic regulators of angiogenesis and osteogenesis (Blumenfeld et al., 2002; 
Clines et al., 2007; Edwards and Mundy, 2008; Oshima et al., 2002; Salani et al., 2000; Salvucci and Tosato, 
2012; Serini et al., 2003; Shao et al., 2004; Shigematsu et al., 1999; Tamagnone and Giordano, 2006).
e,f.   Expression of genes encoding critical NOTCH pathway components (e) and activation of Notch- signaling (f) as 
demonstrated gene sets enrichment analysis (GSEA). 
FPKM:  fragments per kilobase of exon per million fragments mapped. NES: normalized enrichment score. FDR:
false discovery rate. *FDR<0.05.
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Figure 5. Identification of IL-33 as a hematopoietic niche factor 
a.  Transcript expression of 34 genes encoding secreted factors significantly enriched (FDR<0.05) in fetal bone 
and regenerating BM ECs (Log2 fold change in comparison to steady-state bone marrow). FDR: false discovery 
rate. FC: Fold Change. 
b.   3x magnification cropped pictures of immunostained fetal hRECs demonstrating protein expression of IL-33. 
White scale bar represents 20 µm.
c,d.   IL-33 mediated expansion of cord blood derived myeloid and lymphoid progenitor cells as demonstrated by 
flow-cytometric cell counting (c) (MPP, multipotent progenitor, CD90-CD45RA-; MLP, multilymphoid progenitor, 
CD90-CD45RA+; HSC, hematopoietic stem cell, CD90+CD45RA- ) (n= 4 independent experiments) and colony-
forming assays (CFU-C) (d) confirming an increase in CFU-GMs (n= 3 independent experiments).
Data represent mean ± s.e.m. *p<0.05, two-tailed unpaired t-test.
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Figure 6. IL-33 promotes osteogenesis and angiogenesis in vitro
a,b.  IL-33 accelerates terminal differentiation of mesenchymal cells towards matrix-depositing osteoblasts 
as demonstrated by Alizarin red-staining (a) and colorimetric assessment of calcium deposition (b) (n= 3 
independent experiments). 
c.   Knockdown of IL-33 inhibits expansion of HUVECs. Quantification of the total number of HUVECs over time 
(combined data of n= 3 independent experiments). 
Data represent mean ± s.e.m. *p <0.05, two-tailed unpaired t-test.
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Figure 7. Recombinant IL-33 expands hematopoietic progenitors in vivo 
a.  Representative FACS plots of PBS vs IL-33 treated mice depicting the distribution of hematopoietic (progenitor) 
populations. Lin-: Lineage-negative cells. LK: Lin-, c-KIT+, Sca-1- cells. LKS: Lin-, c-KIT+, Sca-1+ cells. LS: Lin-, c-KIT-, 
Sca-1+ cells. MEP: LK, CD16/32-, CD34- cells, megakaryocyte-erythroid progenitor. GMP: LK, CD16/32+, CD34+ cells, 
granulocyte-macrophage progenitor. CMP: LK, CD16/32-, CD34+ cells, common myeloid progenitor. HPC-1: LKS, 
CD48+, CD150- cells, hematopoietic progenitor -1. HPC-2: LKS, CD48+,CD150+ cells, hematopoietic progenitor-2. 
MPP: LKS, CD48-CD150- cells, multipotent progenitor. HSC: LKS, CD48-CD150+ cells, hematopoietic stem cell.
b.  Total BM counts of GMP, LKS, HPC-1, HSC and LS populations in PBS (n=10) and IL-33 (n=5) treated mice. 
Data represent mean ± s.e.m. *p<0.05, **p<0.01, two-tailed unpaired t-test.
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EXPERIMENTAL PROCEDURES
Human bone marrow samples
Bone marrow (BM) aspirates of AML patients were collected at diagnosis, 17 days after 
start chemotherapy (3+7 schedule anthracycline and cytarabin) and upon achievement of 
complete remission (median age: 65 years, range 28-76). The time point of 17 days after 
start of chemotherapy represents the neutropenic phase, 10 days after administration of 
chemotherapy and on average 4 days before recovery of neutropenia. Control marrow was 
obtained by aspiration from donors for allogeneic transplantation (median age: 40 years, 
range 39-48) after written informed consent. In addition, trabecular hip bone was collected 
from patients undergoing hip replacement surgery (median age: 55 years, range 22-71). 
Human fetal long bones (median age: 18 gestational weeks, range 15-20) were obtained 
from elective abortions. Gestational age was confirmed by ultrasonic measurement by 
measurement of skull diameter and femoral length. The use of human samples was 
approved by the Institutional Review Board of the Erasmus Medical Center, the Netherlands, 
in accordance with the declaration of Helsinki with informed consent. 
RNA Sequencing and GSEA analysis 
RNA of sorted cells was extracted according to the manufacturer’s instructions for RNA 
isolation with GenElute LPA (Sigma). cDNA was prepared using the SMARTer procedure 
(SMARTer Ultra Low RNA Kit (Clonetech). Library preparation and RNA-sequencing was 
performed as previously described and validated for low-input (Chen et al., 2016). Finally 
gene set enrichment analysis (GSEA) was performed on the FPKM values using the curated 
C2 collection of gene sets within MSigDB (Subramanian et al., 2005).
Mice and in vivo procedures
C57BL/6JOlaHsd wild-type mice were purchased from Envigo. Animals were maintained in 
specific pathogen free conditions in the Experimental Animal Center of Erasmus MC (EDC). 
To study the murine niche in regenerative conditions, adult mice (7-12 weeks old) were 
intraperitoneally administered with 250 mg/kg 5-fluorouracil (5-FU) and then sacrificed 7 
days after 5-FU treatment. To study the effect of rmIL-33 on steady-state hematopoiesis 
and the BM niche, adult mice (7-14 weeks old) were intraperitoneally injected with 2 µg of 
recombinant IL-33 (580504, Biolegend) or PBS vehicle control daily for 6 consecutive days 
and then sacrificed. 
All mice were sacrificed by cervical dislocation. Mouse bone marrow (BM) and bone fraction 
cells were isolated as previously described (Zambetti et al., 2016). Peripheral blood was 
collected from the submandibular vein in K2EDTA-coated microtainers (BD) and analyzed 
using a Vet ABC counter (Scil Animal Care). Animal studies were approved by the Animal 
Welfare/Ethics Committee of the EDC in accordance with legislation in the Netherlands 
(approval No. EMC 4015).
Characterization of endothelial cells associated with hematopoietic niche formation in humans identifies IL-33 
as an anabolic factor
58
Liquid culture of CD34+ cord blood cells 
20,000 CD34+ cord blood (CB) cells in 200 µl per well were cultured in StemSpan™ SFEM 
(Stem cell technologies, cat. 9600) with Stem Cell Factor (SCF) (50 ng/ml, Cellgenix, Freiburg, 
Germany), in a flat-bottom 96-well plate, at 37ºC and 5% CO2. 2 µl mQ solution containing 
only recombinant human IL-33 protein (ProSpec, cat. CYT-425) or just mQ (vehicle control) 
was added to the medium for a final concentration of 25 ng/ml IL-33 or 1% mQ, respectively. 
The medium was refreshed every 3 or 4 days and cells collected at day 7 for FACs analysis or 
for hematopoietic colony forming-unit assay.
Culture of human BM-derived mesenchymal stromal cells
Human BM-derived mesenchymal stromal cells (BMDSCs) (PT-2501, Lonza) were cultured 
as described previously (Brum et al., 2015). For osteogenic differentiation, BMDSCs were 
cultured in osteogenic induction medium (αMEM medium containing 10% heat-inactivated 
FCS supplemented with 100 nM dexamethasone, 10 mM β-glycerophosphate) with 
recombinant human IL-33 (250 ng/ml) or mQ vehicle control for 3 weeks. Medium was 
refreshed every 3-4 days. 
Culture of and shRNA-mediated knockdown of IL-33 in HUVECs
Human umbilical vein endothelial cells (HUVECs) were expanded in EGM-2 Bulletkit medium 
(CC-3156 & CC-4176, Lonza). RNA interference was achieved by lentiviral transduction. Briefly, 
short hairpin RNAs against IL-33 (sh19:TRCN0000135845 and sh20: TRCN0000135846) 
and a non-target control (shControl: SHC002 [SHC]) cloned in the pLKO.1 backbones were 
obtained from the Mission TRC shRNA library (Sigma-Aldrich). Lentiviral shRNAs were 
produced in HEK293T cells after cotransfection of shControl, sh19, or sh20 together with 
the packaging plasmids pSPAX2 and pMDG.2. HUVECs were infected with lentivirus for 24 
hours and selected for 5 days with 2µg/mL of puromycin.
Statistics
Statistical analyses were performed using Prism 5 (GraphPad Software). Unless otherwise 
specified, unpaired, 2-tailed Student’s t test (single test for comparison of two means) or 
1-way analysis of variance followed by Bonferroni correction for multiple comparisons were 
used to evaluate statistical significance, defined as P<0.05. All results in bar graphs are mean 
value ± standard error of the mean. 
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SUPPLEMENTAL INFORMATION
Table S1
Gene Name Cluster of differentation FDR FC Avg FPKM AML D17 Avg FPKM Healthy CTRL
DPP4 CD26 4.30E-06 42.06162224 1.447326333 0.018322079
ENG CD105 1.61E-03 8.55449896 15.62384567 1.547395714
VCAM1 CD106 3.81E-06 50.16296233 88.93116733 0.804735029
LIFR CD118 2.08E-02 10.1185124 0.1064362 0.016143224
IL1R1 CD121a 1.54E-03 22.29341884 1.835577597 0.040494024
CDH5 CD144 4.26E-03 22.72755944 4.79532 0.072456899
CXCR3 CD183 1.04E-02 6.439581287 4.524633333 1.938153714
CCR2 CD192 1.09E-03 5.554609242 17.7306 4.429592857
PROCR CD201 1.03E-03 19.40383328 7.131228667 0.224176357
TSPAN7 CD231 2.61E-05 24.32565573 54.17457 1.558463086
TNFSF10 CD253 1.16E-02 5.826945634 10.84400633 1.776891571
CD300LG CD300g 1.90E-04 38.86795899 14.576502 0.166514471
NRP1 CD304 3.82E-06 47.01754435 9.396109867 0.113237357
KDR CD309 1.69E-02 18.71674562 6.977216 0.077225637
FZD4 CD344 1.50E-06 45.00592407 2.850081333 0.043208416
S1PR1 CD363 1.33E-03 13.72492829 11.43101533 0.575994457
Supplemental Table 1. Related to Figure 1. Differential expression of candidate membrane markers of endothelial 
cells associated with regeneration after chemotherapy 
Genes encoding cluster of differentiation antigens overexpressed in endothelial cells (CD45-CD235-CD31+CD9+) in 
aspirates obtained from regenerative marrow (n= 3) compared to postnatal steady-state BM (n= 7). FC: Fold change. 
FPKM: fragments per kilobase of exon per million fragments mapped. BM: bone marrow. FDR: false discovery rate.
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SUPPLEMENTAL FIGURES
Figure S1
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Supplementary Figure 1. Related to Figure 2. CD105-expressing endothelial cells are enriched in collagenased 
bone of mice after chemotherapeutic injury
a.  Representative FACS plots revealing the enrichment of a CD105-expressing endothelial cells (ECs) in collagenased 
bone after administration of 5-fluoroucil. Gating strategy for identification of murine ECs is also depicted (see also 
figure 2). BF=Bone fraction.
b.  Frequency of CD105+ ECs within collagenased bone of mice in steady-state (n=3) and after administration of 
5-fluoroucil (n=5). Data represent mean ± s.e.m. **p <0.01, two-tailed unpaired t-test. S.S=Steady-state. 5-FU=5-
fluorouracil.
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Figure S2
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Supplementary Figure 2. Related to Supplemental Table 1, Figure 4 and 5. Transcriptional signatures of fetal 
CD105+ ECs 
a.   Transcript expression of membrane proteins (CD markers) in fetal bone CD31+CD105+ ECs compared to steady-
state BM ECs. The overlap with transcripts identified in ECs isolated from D17 BM (Table S1) supports the 
notion that the enrichment of these transcripts in ECs in the regenerative marrow is caused by overexpression 
in the subset of CD105+ ECs.
b,c.   GSEA plots demonstrating activation of HIF1a signaling (b) and gene sets associated with VEGF, WNT and stem 
cells (c) in fetal hRECs compared to steady-state BM. GSEA: gene sets enrichment analysis. 
d.   Transcript expression (Log 2 fold change) of cognate receptors of candidate secreted proteins (Figure 5A) in 
fetal hRECs and ECs of regenerative marrow compared to steady-state bone marrow. 
e.   Transcript abundance of molecules associated with regeneration previously described in murine studies (Doan 
et al., 2013; Gur-Cohen et al., 2015; Kopp et al., 2005; Nakamura-Ishizu et al., 2012; Winkler et al., 2012).
*<FDR 0.05. FDR: false discovery rate. FPKM: fragments per kilobase of exon per million fragments mapped. BM: 
bone marrow. NES: normalized enrichment score. FC: Fold Change.
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 Figure S3 
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Supplementary Figure 3. Related to Figure 3. In situ immunohistochemistry of CD31+CD105+ endothelial cells in 
human fetal and postnatal bone marrow 
a.  Hematoxylin and eosin, CD31, and CD105 staining in consecutive serial sections of fetal and adult trabecular 
bone. CD31+CD105+ vessels (indicated by black arrowheads) were readily detected in the fetal bone, but at much 
lower frequency in postnatal trabecular bone. Asterisks highlight sinusoidal endothelium, marked by CD105 
expression and concomitant low or lack of CD31 expression. Note: hematopoietic elements with high CD31 
expression (indicated by black arrows) represent megakaryocytes. Representative 5x and 20x magnified images. 
Scale bars represent 100 µm.
b.  Quantified total number of CD31+CD105+ vessels per 5x magnification field in trabecular areas of human fetal 
(n=5) and postnatal trabecular bone (n=4). Data represent mean ± s.e.m. **p <0.01, two-tailed unpaired t-test. 
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Figure S4 
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Supplementary Figure 4. Related to Figure 5. Representative FACS plots of cord blood stem/progenitor cells 
exposed to recombinant IL-33 for one week
Top, representative example of the single platform flow cytometric assay to quantify total cell number. Total 
number of mononuclear cells were calculated using the total number of MNC and beads events recorded using the 
quantification formula described in Experimental Procedures. Note that the MNC/Beads ratio in the vehicle control 
(VC) sample approximates 0.5, whereas the IL-33 treated sample is 2.0, indicating an a 4-fold increase of MNC in 
comparison with VC. 
Bottom, characterization of the MNCs based on CD marker expression. CD34+CD38lo MNCs were identified as 
hematopoietic stem and progenitor cells (HSPCs). HSPCs were further subdivided based on CD90 and CD45RA 
expression. CD90+CD45RA- cells were defined as hematopoietic stem cells (HSCs), CD90-CD45RA- cells classified as 
multipotent progenitor cells (MPP), and CD90-CD45RA+ cells as multilymphoid progenitors (MLP).
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Figure S5 
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Supplementary Figure 5. Related to Figure 6. Effect of recombinant IL-33 on bone marrow-derived stromal cells 
and validation of shRNA-mediated IL-33 knockdown in HUVECs 
a,b.  The total number of bone marrow-derived mesenchymal cells (BMDSCs) and their CFU-F capacity is not affected 
after treatment with recombinant IL-33 in osteogenic conditions. (a) Quantification of the total number of 
BMDSCs kept in regular culture medium (n=2), osteogenic induction medium (n=2) and osteogenic induction 
medium containing recombinant IL-33 (n=2). (b) Quantification of the colony-forming unit-fibroblast (CFU-F) 
capacity of BMDSCs kept in regular culture medium (n=2), osteogenic induction medium (n=2) and osteogenic 
induction medium containing recombinant IL-33 (n=2). 
c,d.  Validation of shRNA-mediated IL-33 knockdown in HUVECs. (c) Transcript analysis of IL-33 by quantitative 
polymerase chain reaction (qPCR) demonstrates efficient knockdown of IL-33 in HUVECs transduced with 
two independent shRNA (sh19 and sh20) compared to a scramble hairpin control (SHC). (n= 4 independent 
experiments). (d) Representative Western Blot analysis confirming knockdown of IL33 at the protein level. 
R.P=recombinant protein IL-33. Protein ladder has been cropped out from both gel figures. 
Data represent mean ± s.e.m. *p <0.05, two-tailed unpaired t-test.
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Supplementary Figure 6. Related to Figure 7. IL-33 promotes expansion of myeloid cells 
a.  Total lineage-negative cell counts in PBS (n=10) and IL-33 treated (n=5) mice. Data represent mean ± s.e.m. 
*p<0.05, unpaired t-test.
b.  Colony-forming assay (CFU-C) on total BM of PBS (n=2) and IL-33 (n=2) treated mice. Data represent mean ± 
s.e.m. Experiments were performed in triplicate.
c.  Total bone marrow cellularity and Lin-, c-KIT+, Sca-1- cell counts in PBS (n=10) and IL-33 treated (n=5) mice. Data 
represent mean ± s.e.m. 
d.  Representative FACS plots demonstrating an increased frequency of monocytes/macrophages in the peripheral 
blood (PB) and bone marrow (BM) of IL-33 treated mice. 
e.  Total PB and BM counts of monocytes/macrophages and neutrophils in PBS-treated (n=3 for PB and n=2 for BM) 
and IL-33 treated (n=3 for PB and n=2 for BM) mice. 
Data represent mean ± s.e.m. **p<0.01, two-tailed unpaired t-test.
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Figure S7 
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Supplementary Figure 7. Related to Figure 7. Recombinant IL-33 alters the architecture of the BM niche
a,b.  Representative FACS plots of PBS (n=3) vs IL-33 treated (n=3) mice depicting the distribution of niche (CD45-
Ter119-) cells within the BM. ECs were identified by CD31. Stromal (CD31-) cells were further defined as 
SCA-1+CD51+ cells (MSCs) or SCA-1-CD51+ cells (OBCs). IL33 administration resulted in a relative increase of 
CD31+CD105+, MSC and OBC populations within the niche. 
Data represent mean ± s.e.m. *p<0.05, two-tailed unpaired t-test. 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Cell isolation from human bone (marrow)
Freshly obtained BM aspirates of AML Day 17 patients were diluted 1:25 with red blood cell 
lysis solution (NH4Cl 0.155 M, KHCO3 0.01 M, EDTA-Na2.2H2O 0.1 M, pH 7.4) and incubated 
for 10 min at room temperature. Mononuclear cells (MNCs) were collected by centrifugation 
and washed once with PBS+0.5%FCS. 
Fetal BM MNCs were isolated by gently crushing fetal long bones (femora, tibiae, fibulae, 
humeri, radii and ulna) in PBS+0.5%FCS using a mortar and pestle and passing subsequent 
cell suspension through a 40-µm filter in a 50 ml collection tube. Simultaneously, bone 
fragments were digested with 0.25% collagenase type I (Stem Cell. Cat#07902) for 45 
minutes at 37°C, vortexing every 15 minutes. Excess PBS was added to the solution and 
filtered through a 40-µm filter in a collection tube. Next, both BM and bone fragment cell 
suspensions were washed once with PBS+0.5%FCS and were subsequently cleared from 
erythrocytes with IOtest3 lysing solution (Beckman Coulter. Cat#A07799), according to 
manufacturer’s instructions. 
For adult hip bone cells, trabecular bone was gently crushed using a mortar and pestle and 
resulting bone fragments were processed as described for fetal bone cells.
Fluorescence active cells-sorting (FACS) of human BM niche cells
Prior to cell sorting, FACS antibody incubations were performed in PBS+0.5%FCS for 20 
minutes on ice in the dark with the following antibodies using optimized dilutions: CD45 
(clone HI30, 1:100), CD271 (clone ME20.4, 1:100), CD235a (clone HI264, 1:100), CD31 
(clone WM59, 1:100), CD9 (clone HI9a, 1:100) from Biolegend, and CD105 (clone SN6, 1:50) 
from eBioscience. The indicated populations of interest were sorted using a FACS ARIAIII 
Cell Sorter (BD Biosciences). Dead cells were gated out using 7AAD (Stem-Kit Reagents) 
after MNC selection and doublets exclusion. For RNASeq, cells were directly sorted in 800µl 
Trizol (Ambion) for RNA isolation. RNAse free non-stick micro-tubes (Ambion) were used to 
prevent pre-digestion of RNA. 
Flow cytometry on murine peripheral blood and bone (marrow) cells
To identify murine hematopoietic stem and progenitor cells (HSPCs), BM cells were first 
co-stained with a cocktail of biotin-labelled antibodies against the following lineage (Lin) 
markers: Gr1 (RB6-8C5), Mac1 (M1/70), Ter119 (TER-119), CD3e (145-2C11), CD4 (GK1.5), 
CD8 (53-6.7) and B220 (RA3-6B2) (all from BD Biosciences). After washing, cells were 
incubated with Pacific Orange-conjugated streptavidin (Life Technologies) and the following 
antibodies: APC anti-c-Kit (2B8), PE anti-CD34 (HM34), Pacific Blue anti-Sca1 (D7), Alexa 
Fluor 700 anti-CD48 (HM48-1), PE-Cy7 anti-CD150 (TC15-12F12.2) (all from Biolegend), and 
APC/Cy7 anti-CD16/32 (56054, from BD Biosciences). To analyze murine differentiated cells, 
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we used APC anti-Gr1 (RB6-8C5), PE-Cy7 anti-Mac1 (M1/70), Pacific Blue anti-B220 (RA3-
6B2) antibodies (all from Biolegend). To define murine niche cells, BM and bone fraction cell 
suspensions were stained with the following antibodies: APC-Cy7 anti-CD45.2 (104), BV510 
anti-Ter119 (TER-119), PE-Cy7 anti-CD105 (MJ7/18), PE anti-CD51 (RMV-7), Pacific Blue 
anti-Sca1 (D7) (all from Biolegend), and PE-CF594 anti-CD31 (MEC 13.3, BD Biosciences). 
IL-33 expression was assessed in BM cells fixed and permeabilized with Cytofix/Cytoperm 
Fixation/Permeabilization Solution Kit (BD Biosciences) by incubating cells with PE anti-IL33 
(IC3626P, R&D Systems) diluted in 1X Perm/Wash buffer (BD Biosciences).
CD31 and CD105 in situ immunofluorescence and immunohistochemistry 
4 μm thick sections of paraffin-embedded BM biopsies were obtained from benign 
lymphoma patients without evidence of intramedullary localization. Fetal femurs were fixed 
in 4% formaldehyde for 24 hours and decalcified in 12.5% EDTA overnight. Fetal femurs were 
subsequently embedded in paraffin and sliced with a Micron HM355Smicrotome (Thermo 
Scientific) to create 4 μm thick sections. 
For in situ immunofluorescence, deparaffinizing and antigen retrieval of the sections were 
performed with CC1 (Ventana 900-124) at 97oC for 64 minutes in a Ventana BenchMark 
ULTRA automatic staining system (Ventana Medical Systems, Tuscon, AZ). Next, murine 
anti-human CD31 (Cell Marque 760-4378) and rabbit anti-human CD105 (Genetex 
GTX100508_25ul,1:100) primary antibodies were manually added to the sections and 
incubated in the Ventana BenchMark ULTRA automatic staining system for 60 minutes 
at 36oC. After thorough washing with PBS/Tween 0.1%, sections were incubated for 30 
minutes with a biotinylated rabbit anti-mouse secondary antibody lacking the FC fragment 
(DAKO E413), followed by washing in PBS/Tween20 0.1% and a 30 minute incubation with 
Cy™3-streptavidin (Jackson ImmunoResearch 016-0160-084). Next, avidin/biotin blocking 
was performed (Vector Laboratories P-2001). After thorough washing with PBS/Tween 0.1%, 
sections were incubated for 30 minutes with a biotinylated swine anti-rabbit secondary 
antibody (DAKO E431), followed by washing in PBS/Tween20 0.1% and a 30 minute 
incubation with FITC- streptavidin (Jackson ImmunoResearch 016-010-084). Finally, sections 
were mounted with DAPI-containing (1:2.000) vectashield (Vector Laboratories H-1000). 20x 
magnified Z-series images were acquired with a Leica TCS SP5 confocal microscope using the 
LAS software (Leica Microsystems). Briefly, after deparaffinization sectioned specimens were 
processed for 64-minute antigen retrieval with CC1. After 20-minute incubation at 36oC with 
either previously described primary antibodies for CD31 and CD105 (1:500), detection was 
performed using UltraView DAB IHC Detection Kit (760-500, Ventana). The sections stained 
with CD31 and CD105 were counterstained with hematoxylin II (Ventana Ref.: 790-2208). 
Images were acquired with a ZEISS AxioPhot microscope using cellSens Entry 1.9 software 
(Olympus Corporation).
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IL-33 immunofluorescence 
FACS-isolated hRECs, obtained from fetal bones and BM, were collected in PBS, cytospun 
on a glass slide for 3 minutes at 500 rpm using a Cytospin 4 centrifuge (Thermo Scientific), 
and fixed in 3% PFA/PBS for 15 minutes on ice. After washing with PBS 3 times, cells were 
permeabilized for 2 minutes in 0.15% Triton-X100/PBS and then incubated in 1%BSA/PBS 
for 1 hour at room temperature to block aspecific binding sites. Cells were next stained 
overnight at 4°C with polyclonal goat anti-human IL-33 antibody (AF3625, R&D, 20 µg/
ml in 1%BSA/PBS ) or goat IgG isotype control antibody(Catalog # AB-108-C). Slides were 
washed twice with PBS for 5 minutes and incubated for 1 hour at 37°C with Alexa Fluor 488- 
conjugated donkey anti-goat antibody (A-11055, Invitrogen, 1:200, in 1%BSA/PBS). After 2 
washes in PBS, slides were mounted in VECTASHIELD Mounting Medium with DAPI (Vector 
Laboratories). 63x magnified Z-series images were acquired with a Leica TCS SP5 confocal 
microscope using the LAS software (Leica Microsystems). For in situ immunohistochemistry 
consecutive serial sections of the benign lymphoma patients and fetal femur biopsies were 
stained for hematoxylin and eosin, CD31 and CD105 separately with the Ventana Benchmark 
Ultra automated staining system. 
Hematopoietic stem progenitor cell isolation from umbilical cord blood
Umbilical cord blood (CB) was collected in a 300 ml bag filled with 20ml of the anticoagulant 
citrate phosphate dextrose (T2950, Fresenius Kabi), after receiving informed consent from 
the mother, and retrieved within 24 hours after collection. MNCs were obtained by using 
a standard Ficoll gradient protocol (1114547, Axis-Shield). CD34+ CB HSPCs were further 
isolated by magnetic-activated cell sorting (MACS). Briefly, MNCs were incubated with a 
magnetically coated anti-CD34 antibody (120-000-268, Miltenyi Biotec) and FcR blocking 
reagent (120-000-265, Miltenyi Biotec) in MACS buffer at 4°C for 30 minutes. After washing, 
CD34+ CB HSPCs were isolated using a LS column (130-042-401, Miltenyi Biotec) and purity 
was further enriched by performing an additional MACS selection using two MS columns 
(130-042-201, Miltenyi Biotec). Purity of the isolated cell population was confirmed with 
fluorescence-activated cell sorting (FACS). 
Quantification and multiparametric immunophenotyping of cultured CB CD34+ 
cells
Cultured CB cells were thoroughly resuspended and collected for the single platform 
flowcytometric assay (to determine absolute cell counts) and for immunophenotyping (to 
specify HSPC subpopulations), respectively. For the single platform flowcytometric assay, 
cultured cells were incubated with CD34-PE-Cy7 (348811, BD Biosciences, 1:50) and CD45-
PE-Cy5 (557075, BD Biosciences, 1:50) antibodies, and a calibrated number of flow-count 
fluorosphere beads (7547053, Beckman Coulter). In addition, 4’,6-diamidino-2-phenylindole 
(DAPI) (1:5.000) was used to distinguish between living and dead cells. The total number of 
living MNC per µl in (n) a well was calculated using the following formula: n= ((number of 
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MNC events recorded * bead concentration)/number of recorded single beads)/ (volume 
cells/ volume beads). For immunophenotyping, cultured cells were incubated with Lin-FITC 
(22-7778-72, eBiosciences, 1:25), CD34-PE-Cy7 (348811, BD Biosciences, 1:50), CD38-PerCP-
Cy5.5 (561106, BD Pharmingen, 1:60), CD90-PE (12-0909-42, eBiosciences, 1:30), CD45RA-
APC-H7 (560674, BD Pharmingen, 1:30) and DAPI. Antibody incubation for FACs took place 
as previously described. The total number of a specific subpopulations was determined by 
multiplying the absolute number of living MNCs with the frequencies of the populations, 
determined with immunophenotyping, of interest. Flowcytometric analysis was performed 
using a BD LSRII (BD Biosciences, San Jose, CA, USA) and data was analyzed using FlowJo 
software (Tree Star Inc, Ashland, OR, USA). 
Human hematopoietic colony forming-unit assay
To further assess the effect of recombinant human IL-33 on the hematopoietic potential 
of cultured CB cells, we performed a colony-forming unit assay (CFU). Input equivalent 
of 2000 7-days cultured CD34+ cells of each condition (rhIL-33 vs vehicle control) was 
resuspended in 400 µl Iscove’s Modified Dulbecco’s Medium (IMDM) and transferred to 3.6 
ml of methylcellulose (MethoCult H84434, StemCell Technologies). Cells were then plated in 
triplicate in 1 cm² petri-dishes(1 ml/dish) and were kept at 37ºC and 5% CO2. Colonies were 
counted after 12-14 days. 
Osteogenic differentiation and mineralization assays
BMDSC extracts were harvested at the end of culture by scraping the cells in PBS/triton 1% 
and storing them at −80 °C for biochemical analyses (Bruedigam et al., 2011). After scraping, 
PBS/triton 1%/0.24 M HCL was added to the wells and kept overnight at 4 °C to release 
calcium ions from the matrix deposition. Cell extracts were briefly sonicated (Soniprep 150, 
Sanyo) to produce cell lysates and incubated overnight with 6 M HCL. In short, calcium 
content was determined colorimetrically by adding o-cresolphthalein complexone to the 
well contents and cell lysates and measuring the absorbance of the resulting chromophore-
complex at 595 nm.
Alternatively, cells were fixed in 70% ethanol (vol/vol) on ice for an hour and after washing 
with PBS, stained for 10–20 min with alizarin Red S solution (saturated Alizarin Red S (Sigma) 
in demineralized water adjusted to pH 4.2 using 0.5% ammonium hydroxide). 
Human bone marrow fibroblast colony-forming unit assay
BMDSCs were first either cultured in αMEM medium containing 10% heat-inactivated FCS, 
or osteogenic induction medium containing recombinant human IL-33 (250 ng/ml) or mQ 
vehicle control for 1 week. After culture, total number of cells per condition were quantified 
with a Bürker counting chamber. Next, 50 cells per 0.32 cm2 (1 well of a 96-well plate) 
were seeded in ɑMEM supplemented with 20% fetal bovine serum and 1% penicillin/
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streptomycin. On day 14, dishes were fixed with 70% ethanol (vol/vol) and stained with 
Giemsa. CFU-F colonies were counted as previously described (Chen et al., 2016).
Validation of IL-33 knockdown in HUVECs
For transcriptional analyses, HUVECs were harvested and collected after puromycin selection 
in TRIzol Reagent (Life Technologies). RNA isolation, conversion to cDNA and qPCR were 
performed accordingly to previously described methods (Zambetti et al., 2015) using the 
SuperScript II Reverse Transcriptase (Thermo Fisher Scientific). For qPCR, expression levels 
were obtained using the ddCt method using GAPDH as an internal control. The following 
primers were used: GAPDH-Fw: GTCGGAGTCAACGGATT; GAPDH-Rv: AAGCTTCCCGTTCTCAG; 
IL-33-Fw: GGAAGAACACAGCAAGCAAAGCCT; IL-33-Rv: TAAGGCCAGAGCGGAGCTTCATAA.
For protein analyses, cells were lysed in Carin lysis buffer (20 mM Tris-HCl pH 8.0, 138 
mM NaCl, 10mM EDTA, 100 mM NaF, 1% Nonidet P-40, 10% glycerol, 2mM NA-vanadate) 
supplemented with 0.5 mM DTT and the protease inhibitor SigmaFast (Sigma Aldrich). 
Equal amounts of proteins were denatured and separated on a Novex NuPage 4-12% Bis-
Tris Gradient gel (Life Technologies) and transferred to Protran BA83 blotting paper (GE 
Healthcare Sciences). After blocking with 5% BSA, membranes were incubated overnight 
at 4°C with a polyclonal goat anti-IL-33 primary antibody (AF3625, R&D systems). Actin 
was used as a loading control and detected with a mouse anti-actin antibody (A5441 Sigma 
Aldrich). Western blots were scanned and processed using an Odyssey Infrared Imager (Li-
COR Biosciences).
To monitor the expansion of HUVECs after shRNA mediated knockdown of IL-33 after 
puromycin selection, HUVECs were re-plated and seeded at 300.000 cells in a T-25 flask and 
grown in EGM-2 medium containing 2µg/ml of puromycin. HUVECs were passaged every 2 
to 4 days and total number of cells were quantified using a Casy counter (Roche Innovatis).
Murine hematopoietic colony forming-unit assay
To assess the myeloid progenitor capacity of whole BM from mice treated with PBS or IL-33, 
BM cells were cultured in methylcellulose containing murine SCF (10 ng/ml), IL-3 (100 ng/ml, 
purified from supernatant of CHO cells), IL-6 (10 ng/ml) and GM-CSF (10 ng/ml). Cytokines 
were purchased from PeproTech, if not otherwise mentioned. Specifically, 20000 BM cells 
per condition were resuspended in 400 µl IMDM and transferred to 3.6 ml of Methocult 
3231 (StemCell Technologies). Cells were then plated in triplicate in 1 cm² petri-dishes(1 ml/
dish) and were kept at 37ºC and 5% CO2. Colonies were counted after 5-7 days.
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LIST OF ABBREVIATIONS
5FU  5-fluorouracil
α-SMA  Alpha smooth muscle actin
ADM  Adrenomedullin
AGM  Aorta-gonad-mesonephros
AML  Acute myeloid leukemia
ANC  Absolute neutrophil count
ANOVA  One-way analysis of variance
APLN  Apelin
BF Bone fraction
BM  Bone marrow
BMP4 Bone morphogenetic protein 4
BMDSC  BM-derived stromal cells
BMSC  Bone marrow stromal cell
BrdU  5-bromodeoxyuridine
CAR  CXCL12-abundant reticular
CD  Cluster of differentiation
CFU-C  Colony-forming unit cell
CFU-F Colony-forming unit fibroblast
CFU-GM  Colony-forming unit granulocyte-monocyte
CLP  Common lymphoid progenitor
CM  Central memory
CMP  Common myeloid progenitor
CXCL4  C-X-C motif ligand 4 
CXCL12  C-X-C motif chemokine ligand 12
D17  Day 17
DKK1  Dickkopf-1
E  Embryonic day
EC  Endothelial cell
ECFC  Endothelial colony forming cell
EDN1  Endothelin 1
EFNA1 Ephrin A1
EGF  Epidermal growth factor
EHT Endothelial-to-hematopoietic transition
EM  Effector memory 
EMT  Epithelial-to-mesenchymal transition
EndMT  Endothelial-to-mesenchymal transition 
ES  Enrichment score
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ESELE  Selectin E
FACS  Fluorescence activated cell sorting
FC  Fold change
FDR  False discovery rate
FGF1  Fibroblast growth factor 1
FOP  Fibrodysplasia ossificans progressiva
FPKM  Fragments per kilobase of exon per million fragments mapped
G-CSF  Granulocyte colony-stimulating factor
GAG  Glycosaminoglycan
GM-CSF  Granulocyte-macrophage colony-stimulating factor
GMP  Granulocytic/macrophage progenitor
GO  Gene ontology
GSEA  Gene set enrichment analysis
HPC  Hematopoietic progenitor cell
hREC Human regeneration-associated EC
HUVEC  Human umbilical vein endothelial cell
HSC  Hematopoietic stem cell
HSPC  Hematopoietic stem and progenitor cell
IL-1β  Interleukin 1 β
IL-33  Interleukin 33
IR  Ionizing radiation
Jag1  Jagged-1
Jag2  Jagged-2
LEPR  Leptin receptor
LNGFR  Low-affinity nerve growth factor receptor
LT-HSC  Long-term HSC
MACS  Magnetic-activated cell sorting
MEP  Megakaryocytic/erythroid progenitor
MFI  Mean fluorescence intensity
MLP  Multilymphoid progenitor
MMRN2  Multimerin 2
MNC  Mononuclear cell
MPP  Multipotent progenitor
MSC  Mesenchymal stromal cell
NES  Normalized enrichment score
NK  Natural killer cell
N  Naive
OBC  Osteoblastic cell
OLC  Osteo/chondrolineage (progenitor) cell
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Ocn  Osteocalcin
PCA  Principal component analysis
PLAT  Tissue-type plasminogen activator
PTN  Pleiotrophin
RBC  Red blood cell
rmIL-33  Recombinant murine IL-33 
rhIL-33  Recombinant human IL-33 
ROS Reactive oxygen species
Sca-1  Stem cell antigen 1
SCF  Stem cell factor
S.E.M  Standard error of the mean
SEMA3A  Semaphorin-3A
SLAM  Signaling lymphocyte activation molecule
SNAI1  Snail family transcriptional repressor 1
SNAI2  Snail family transcriptional repressor 2
SNS  Sympathetic nervous system
ST-HSC  Short-term HSC
TEMRA  CD45RA re-expressing cells
TNC  Tenascin C
TFPI  Tissue Factor Pathway Inhibitor
TGF-β  Transforming Growth Factor Beta
TMBD  Thrombomodulin
TNFα  Tumor necrosis factor-alpha 
TPO  Thrombopoietin
TWIST1  Twist Family BHLH Transcription Factor 1
UCB  Umbilical cord blood
WBC  White blood cell
VC  Vehicle Control
VEGFR2  Vascular endothelial growth factor receptor 2
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PHD PORTFOLIO
Name PhD Student: Keane Kenswil PhD Period: January 2014 – January 2020
Erasmus MC Department: Hematology   Promoters:  Prof.dr. H.G.P. Raaijmakers
Research School: Molecular Medicine (MolMed)                            Prof.dr. I.P. Touw
1. PhD Training Year    
  Year  ECTS
General Courses
Photoshop and Illustrator workshop 2014 0.3
Research management for PhD-students 2014 1.0
Research integrity course 2016 0.3
Biomedical English writing course 2017 2.0
Annual Course on Molecular Medicine 2018 0.6
In-depth Courses and Workshops
Molecular aspects of hematological disorders (4x) 2014-2017 2.8
The course on R 2016 1.8
Basic course on SPSS 2018 1.0
Basic course on Python 2019 1.7
Basic course on Microsoft Access  2019 0.3
Two-days Course Bayesians statistics and JASP: Basic & Advanced 2019 0.6
Advanced course on Excel 2019 0.4
Scientific Meetings Department of Hematology
Work discussions (Weekly) 2013-2018 8
Journal club / literature discussions (bi-montly) 2013-2018 7
PhD lunch with invited speaker (Monthly) 2014-2018 2.5
Erasmus Hematology Lectures (Monthly) 2014-2018 2
National/International conferences
Molecular Medicine Day (4x) (Rotterdam) 2014-2017 1.5
European School of Haematology International Conference (Lisbon, Portugal) 2015 0.3
Dutch Hematology Congress (2x) (Arnhem) 2016-2017 0.6
Annual Conference of American Society of Hematology (Atlanta, USA) 2018 0.3
Presentations
Departmental work discussions (Oral, 6x) (Rotterdam) 2014-2017 3.0
Journal clubs (Oral, 3x) (Rotterdam) 2014-2017 1.5 
Dutch Hematology Congress (Oral, 1x) 2017 1.0
Academic Center for Stem Cells and Organoids in REgenerative medicine  2017 1.0
(ACE-SCORE) Day (Oral, 1x)
Annual Conference of American Society of Hematology (Atlanta, US 2018 1.0 
(Poster, 1x)
2. Teaching, Supervision & Organization Activities
Organization and supervision PhD lunch with invited speakers  2015-2016 0.2
Total   41.7
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WORD OF THANKS
Perhaps I’m exaggerating by stating that I never expected to be writing my acknowledgments 
(at least any time soon), but there were times I genuinely thought I’d never reach this point in 
my PhD programme. Achieving this milestone would not have been possible without my own 
niche; in particular the people – to whom I will forever be indebted to for their continuous 
support over the past years – who I would like to thank in the following paragraphs.
Allereerst wil ik mijn promotor Prof.dr. Raaijmakers, Marc, bedanken: U nam mij niet 
alleen aan als een masterstudent, heel lang geleden al, maar u zag (gelukkig voor mij) 
genoeg potentie in mij om mijn onderzoek als volwaardige promovendus voort te zetten. 
De afgelopen jaren heeft u duidelijk aan mij gemaakt wat nodig is om succesvol te zijn in 
wetenschappelijk onderzoek. Naast imponeren met uw gladde praatjes, bent u ook gewoon 
het schoolvoorbeeld geweest van hard werken, hoe vaak ben ik u wel niet tegengekomen 
nog laat in de avond, of in het weekend, op werk. En misschien was de allerbelangrijkste 
les: gericht werken en bewust zijn van wat “the bigger picture” is. Dit heeft mij uiteindelijk 
ook immens geholpen met het (leren) schrijven. Verder heeft u mij ook geleerd om door 
te zetten als het tegenzit en dat tegenslagen in de wetenschap de normaalste zaak van de 
wereld is; uw enthousiasme en gedrevenheid voor onderzoek wist me vaak ook gewoon 
weer te motiveren wanner het nodig was. We waren misschien regelmatig niet met elkaar 
over eens over hoe bepaalde vraagstukken (realistisch) aangepakt moesten worden, maar 
dat was waarschijnlijk ook beter zo, anders had ik niet veel geleerd tijdens mijn periode in 
de Raaijmakers’ groep. Ik ben heel dankbaar hiervoor en wens u en uw groep veel succes 
toe in het maken van nieuwe wetenschappelijke ontdekkingen. 
Prof.dr. Touw, Ivo, mijn tweede promotor, ik heb veel geleerd, en me ook goed vermaakt, van 
uw moeilijke (en ook gewoon legitieme) vragen die vaak levendige discussies deed oplaaien 
tijdens de werkbesprekingen. U stelde ook vaak relevante vragen over mijn experimenten, 
deze hielpen ons het onderzoek naar een hoger niveau te brengen, maar voorkwam ook 
dat we voorbarige conclusies trokken. Verder kon u ook tegengewicht bieden aan Marc en 
kon ik gelukkig naar jou toe gaan voor duidelijk advies wanneer ik er soms niet uitkwam 
met hem. Misschien op de eerste oogopslag niet heel erg wetenschappelijk, maar ik stelde 
ook altijd op prijs hoe je altijd verschillende gerechten wist klaar te maken voor de eet-
evenementen van onze afdeling. Oh en natuurlijk ook bedankt voor het grondig nakijken 
van mijn proefschrift!
I would also like to thank my assessment committee for critically evaluating and approving 
my manuscript. Prof.dr. P. ten Dijke, ik heb u persoonlijk (nog) niet ontmoet, maar u bent 
wel nauw betrokken geweest bij mijn onderzoek, vooral met de meest recente studie over 
EndMT, waar u (en uw groep) ook kritisch aan heeft bijgedragen. Nog bedankt hiervoor. 
Prof.dr. W. E. Fibbe, ook u heb ik (nog) niet ontmoet, maar u heeft ook een belangrijke 
bijdrage geleverd door mijn proefschrift snel op tijd grondig door te nemen, zelfs na wat 
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kleine mankementen met het Hora Finita systeem. Dank hiervoor. Dr. E. Farrell, I’m very 
grateful for our long-time ongoing collaboration that has turned out to be very fruitful, and 
which will hopefully lead to a very nice publication! Your willingness to extend a helping 
hand to our group helped us answer some very important questions brought up by the 
peer reviewers. I would also like to thank you for being the secretary of the committee, and 
keeping Marc updated through the whole process, who in turn could keep me informed on 
the latest developments.  
I would also like to extend my gratitude to the other members of my doctoral committee 
for willing to participate in my defence ceremony. Prof.dr. J.P.T.M van Leeuwen, ik voel me 
vereerd dat u als decaan deel kan nemen in mijn promotieplechtigheid. Ik herinner me 
dat één van mijn eerste collaboratieve bijeenkomsten met jouw onderzoeksgroep was, 
namelijk de “Bone-HSC” meetings op de vijfde verdieping. Dit leidde gelijk naar één van 
de eerste samenwerkingen in mijn onderzoek, wat heel goed verliep, bedankt hiervoor. Dr. 
T. Cupedo, Tom, ik ben u ook heel erg dankbaar voor de verschillende manieren hoe jij mij 
hebt geholpen. Jij hebt je niet alleen (letterlijk) ingespannen om foetaal materiaal voor mijn 
onderzoek te regelen, maar jij heb ook veel constructieve feedback geleverd in twee van mijn 
belangrijkste studies. Ik vond de collaboratieve bijeenkomsten met jouw onderzoeksgroep 
ook altijd heel erg leerzaam. Jouw onderzoeksgroep was ook altijd bereid om mij te helpen, 
en is in zekere mate een weerspiegeling van jou. Dr. G. Krenning, Guido, jouw groep heeft 
ook belangrijke bijdragen geleverd aan mijn werk naar EndMT. Jij hebt ook zelf ervoor 
gezorgd dat nadat jouw PhD-student, Byamba, terug naar Mongolië was vertrokken dat 
onze samenwerking nog vlekkeloos verliep. Bedankt hiervoor. Dr. R. Schneider, Rebekka, 
while I maybe have not worked as closely as my other (former) colleagues with your group, 
I really still appreciate your input and the help you and your group have provided me along 
the way. I hope the common themes shared between our groups will continue to foster 
close (future) collaborations, in particular when it comes to resolving the potential role of 
IL-33 in myelofibrosis. 
Verder wil ik ook de andere groepsleiders van de afdeling Hematologie bedanken die ik heb 
meegemaakt. Speciale dank aan Bob die ik nog regelmatig tegenkwam en mij altijd heel erg 
vrolijk groette, ook al kende u mij eigenlijk niet, en die ook nog vaak de Friday floor meetings 
bijwoonde en daar ook interessante vragen stelde. Dit geldt ook voor Pieter, Frank, Jan, 
Ruud, Moniek, Peter, Eric, Mojca, Stefan en Emma, jullie hebben allemaal op één of andere 
manier mij geholpen, bijvoorbeeld door het doneren van bepaalde protocollen, reagenten, 
cellen, weefsel, of zelfs met het opzetten van nieuwe muizen-breedings. Ook was het gezellig 
om met jullie te babbelen of grappen te maken over jullie eigen PhD-studenten tijdens de 
borrels. 
Of course I would also like to thank my fellow group members, be it former, contemporary, 
as well as recently arrived colleagues, you all had your part in helping me to complete my 
PhD studies. 
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First of all I would like to thank Noemi, you were my daily supervisor during my master 
internship despite you not really benefiting from this task due to our projects not being 
directly related.  Nonetheless you still took your time to teach me basic stuff, such as cell 
culture and genotyping, and helped me to get on my way to conduct my own research 
independently. I appreciated your more hands-off (progressively over time) approach in 
supervising me and liked that you didn’t mind me slacking off from time to time to socialize 
with other fellow (master)students. I think you also set a great example for the rest of the 
students in the lab, and I think this is partly why Marc has such high standards for his PhD 
students, so thanks for that J. 
Athina, while I did not end up being your student, you still helped me out with any questions 
I had for you, even though you already had left the group by then. Also thank you for helping 
to set up the group before I arrived! 
Niken, apppaaa, how I miss our KFC feasts we shared with our fellow (Asian) group members. 
Thank you so much for helping with out with genotyping, FACS and RNA-Sequencing, 
without you the group barely managed to scrape by.
Si, another of the original KFC-crew members! I’m impressed by how you always managed to 
stick to your goals and never got too distracted, despite whatever stressful situations were 
occurring in the lab. It’s particularly impressive that you managed to graduate with minimal 
delays, which is not an easy task in this group. You also have a real knack for presenting, and 
I hope you keep putting it to good use in Singapore! I would like to thank you for giving me 
a lot of constructive feedback during our group-meetings, at least when you were not falling 
asleep haha, and also for organizing a lot of fun social (read: eating a lot of food) events with 
our other lab-mates. 
Ping, the honour and privilege is mine. We have been through so much, and even lived 
together for a while, though I actually did not see you much socially back then since you 
were usually slaving away in the lab until the early morning hours. This was often, if you 
were not procrastinating in the lab or getting distracted by me, due to your dedication to 
getting stuff done perfectly. Because, indeed, what’s the point of doing something if it’s not 
done properly? This is a sentiment I agree strongly with you, and I think this is also why I get 
a long with you not only at professional level, but also a personal level. In fact, we see eye 
to eye on a lot on a lot stuff, in particular what it means to have honor. That said we also 
had some disagreements, and inevitable tensions in the lab, like about Tibet/Taiwen, but 
we always managed to keep it respectful. I have to keep it brief, but I’m sincerely grateful 
that I shared an office, our own private fridge, many dinners, karaoke-borrels, fun festivals, 
and many crazy parties over the years. Also special thanks for helping me out with my mice 
experiments whenever my hands were too shaky! 
Adrian, you bloody Mexican! We both know I would never have gotten to this point 
without you laying the groundwork for me when it comes to the Day 17 and fetal samples. 
For this I will always be grateful to you. Besides these critical scientific contributions, you 
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were also one hell of a roommate to have! The many nights out, but also the nights at 
our place hosting costume parties, including the toga, yoga, Halloween, murder-mystery, 
and Christmas sweater themed events; the utter debauchery would have made Caligula 
blushed. And then not to speak of the countless concerts we attended, such as Nils Vroom, 
The Beach Pixies, Blossoms, Corvalis, Small Blacks, Yucks, Dinosaur Sr., Sonic Seniors, The 
Serial Killer from No Country for Old Men, and The Robert Smiths, what a time to be alive 
indeed. I really hope we manage to attend another festival with the gangbang before all it 
is said and done. There are many more stuff I’m grateful for, but I have to keep it brief. I will 
spare you the platitudes, and simply wish you good luck in whatever you still need to do to 
finish your PhD. Trust the dice.  
Claire, ik wilde net schrijven dat alles gelukkig eindelijk achter de rug is, maar we hebben 
misschien binnenkort nog revisies voor de EndMT paper :’)! Maar nu even serieus, ik ben 
je zeer dankbaar dat jij mijn projecten voorlopig (en niet eventjes) wist over te nemen. 
Zonder jou zouden de foetale monsters in Amsterdam niet verwerkt zijn geweest, en dat 
was ook allemaal net op tijd gebeurd. Jij hebt niet alleen praktisch werk gedaan, zoals FACs 
en RNASeq, maar jij hebt ook gewoon in zijn geheel kunnen bijdragen door jouw eigen 
wetenschappelijke inzichten te verschaffen, zoals bijvoorbeeld bij het analyseren van de 
scRNASeq data, en andere momenten die ik me nu natuurlijk niet meer kan herinneren 
:p. Ik geloof oprecht dat je geschikt zou zijn om zelf een PhD-traject te voltooien! Jij hebt 
in ieder geval het IQ en passie ervoor. Verder was het ook heel gezellig met jou; en hoop ik 
binnenkort met jou en PaOla te kunnen sushi’n. 
Jacqueline, you are the bridge from the former generation to the current one. I’m really 
impressed to see how you’ve developed over time as researcher, like me also starting off as a 
master student, and becoming more confident and taking charge of your own experiments. 
Not only that, but you have also kind of taken up a senior-ish role in the group, making sure 
everyone is doing well or doing stuff properly in the group. I’m really grateful for the several 
times you helped me out with my projects, be it with HiX to help me out with the AML day 
17 samples, or preparing antibody orders, or even performing flow cytometry experiments 
for the EndMT project. I’m sure you will continue to do well in your PhD, and wish you good 
luck in carrying the torch for the newer generation! 
To the other former Post-Docs in our group: Yongyi and Tamar, it’s too bad our periods 
didn’t overlap much in the lab, I would have really liked to soak up more of your knowledge. 
I wish you well in your future scientific pursuits! All active PhD-candidates or Post-Docs 
in our group, Eline, Isabel, LanPeng, and Martijn, I haven’t worked or interacted much 
with you at all, but I still want to thank you for the times I chatted or distracted you in the 
office or hallways and wish you well with your studies! Also a special mention to all former 
students in our group, like Sjoerd, I enjoyed nerding out about stuff like Twitch, I felt like I 
was teenager again.  
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Last but not least of the Raaijmakers’ group, I want to thank PaOla, I often say time is a flat 
circle, and working closely with you these past weeks on the submission for the EndMT 
paper, made me believe this all the more: I started my studies on the niche with a feisty, 
short, intelligent Italian brunette, only for it to finish with another fire-y, small, smart, Italian 
brunette. Though my thesis was technically already approved, you still helped me elevate 
the EndMT paper to another level, not only stylistically with your choice of colours, but also 
literally at a single cell level. For this I really want to say thank you. I’m happy “my project” is 
in your hands now, and I’m sure you will do well. Also like I told Claire, I look forward to our 
sushi dinner to discuss not only how the project is progressing, but also to figure out which 
political system, instead of democracy, would be the best to meet the needs of society. 
I would also like to name a lot of other people from the lab that have helped me out. Special 
thanks to Eric-Sensei, I don’t think I’m exaggerating when I call you the Godfather, or maybe 
even the babysitter of our group, without your guidance we would not gotten much done 
(efficiently or properly) over the past years. I’m especially grateful for the many times you 
helped me out with those pesky western blots and with the shRNA knockdowns. In addition, 
I also appreciated your fine taste in music (most of the times), in particular when it comes 
to our shared love for (post)punk music or The National. We even attended a Sigur Rós 
concert together once with Mr.O! Mr.O, what up my ginger! It’s time to plan Iceland part 
II, it has to happen! Thanks for organizing the many epic (ambrosia) nights, and being part 
of all the crazy adventures we’ve experienced over the years. We also worked a bit in this 
period, and I also want to thank you for helping me out in the lab, be it with confocal, getting 
me extra screen for the PC, or providing me shiny antibodies for immunofluorescence. 
Thanks man! Paulette! Hoe vaak moest jij wel niet lang op het lab blijven, omdat jij mij aan 
het helpen was met FACS-sorteren. Verder hielp jij mij ook zo vaak met het preppen van 
mijn samples voor RNASeq, en was jij ook altijd oprecht geïnteresseerd in hoe het met mij 
ging, en ook met de anderen in de groep, door een luisterend oor aan te bieden. Je was 
soms eigenlijk gewoon een technician binnen onze groep (en ik zou het helemaal niet erg 
gevonden hebben als jij naar de Raaijmakers’ groep was overgelopen), en wil je hiervoor 
hartelijk bedanken! Ik wil ook Nathalie bedanken, jij hebt me ook zo vaak geholpen met het 
sorteren en het verwerken van de foetale botten. Ook vond jij het nooit een probleem als 
ik regelmatig antilichamen kwam gebruiken van jouw groep. Verder kon ik wel lachen om je 
grappen, zoals over “The Great Wall of China”. 
Remco, ik vond het heel gezellig met jou op de 19de verdieping toen ik aanvankelijk begon 
als een masterstudent, en dat bleef ook zo nadat we zelf een eigen plek op de 13de hadden 
gevonden. Ik wil jou ook hartelijk bedanken voor jouw inzet om gedegen RNASeq/GSEA 
analyses uit te voeren. Dit geldt ook voor Mathijs, en ik wil jullie allebei bedanken voor jullie 
geduld met onze vragen over statistiek, bijvoorbeeld wanneer iets nou echt als significant 
beschouwd kan worden. Ik wil ook Elodie bedanken voor het bouwen van de RNASeq-
database website.
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Verder wil ik nog meer mensen bedanken, waaronder de flow-cytometrie operators: Elwin, 
Peter en Michael. Jullie werkten altijd nauwkering en bleven geduldig en flexibel wanneer 
ik samples (nog laat) moest sorteren. Ik wil in het bijzonder Elwin verder bedanken, want 
jij hebt mij ook ontzettend veel geholpen met het vierde hoofdstuk van mijn proefschrift. 
Samen met Lucia hebben jullie mij ook geholpen met opzetten van mijn masterstage. Ik wil 
ook Mariëtte bedanken, jij hebt mij veel geholpen met het isoleren van CD34+ cellen uit 
navelstrengbloed, en je hebt mij vaak cellen gedoneerd. Jasper en Joyce, ik heb misschien 
niet veel direct met jullie gewerkt, maar ik kon altijd leuke grappen met jullie maken. To err 
is human to arr is pirate. 
I would also like to give special thanks to my collaborators, who helped me finish my studies. 
Bram en Marijke, dank jullie wel voor de MSCs en ook voor het duidelijk maken aan mij 
hoe ik ALP-assays moest uitvoeren. Byamba and Callie, thank you for all the cell culture 
and (differentiation assays) you guys performed for the EndMT paper. Callie, it’s about time 
we find another festival or event to celebrate that we can put our PhD-adventure behind 
us! Gonzalo and Andrea Lolli, I also want to thank you for your critical contributions to the 
EndMT paper, I hope you guys don’t mind if I keep pestering you about experimental details 
if any questions pop-up, especially if we end up doing revisions! Dr. Pieter Koen Bos en 
Dr. King Lam bedankt voor de humane (bot) monsters die ik heb kunnen gebruiken in mijn 
studies. Dr. Hans Stoop, jou wil ik ook bedanken voor al de immunohistochemie die jij voor 
mij hebt gedaan, en ik wens je nog succes toe met je jazz-optredens! Ik wil ook het BMT 
lab bedanken voor al de BM samples die jullie aan mij hebben gegeven. Speciale dank aan 
Hennie die mij heeft geleerd hoe ik kolonies moet tellen. 
I’m also much obliged to the colleagues who I shared my office with over the years. Emanuele, 
my paranymph and dear friend, hopefully you have survived the corona-scare with Matteo, 
and will manage to make my ceremony. If not, you will be very difficult to replace, as I don’t 
see anyone easily replicating your rather care-free, bordering on the lackadaisical, attitude 
that is very much appreciated by me. In fact, I’m rather fond of this approach to life as it led 
to many eggtastic eggperiences. At the same time your attitude keeps my rather neurotic 
and impulsive behaviour in check, and whenever we almost came to blows you always knew 
when to walk away (cause you’d get your ass kicked). Kidding aside, as Ping would put it, 
it’s been an honour to have gotten to know you. I look forward to visiting your hometown 
one day so we can play some basketball and eat arrosticini with the locals. Having said that 
I hope I already partially repaid my debt to you by finding you your first Dutch GF. P.S. Sorry 
for dragging you to Welcome to the Future, but it’s your own fault you got sick from eating 
bad fish. Anywho, good luck with your own writing. Cansuuu, thank you for bestowing upon 
me my cute “Keannuu” nickname, I think it actually suits me quite well. You and your daddy 
have made my final years of my PhD so much fun, I’m happy that we not only saw each other 
so often in the lab, but also outside of it! I’m in particularly impressed by how you can keep 
up with me, Ping and your daddy when it comes to eating yummy food. With Ping, me, and 
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also your daddy leaving soon, I hope you won’t get too lonely, but I’m sure you’ll manage, 
since you probably will just keep laughing like a maniac, as you always do. Good luck with 
finishing your projects, you can do it!! Mira, you were never officially my officemate, but 
you practically were with how often you came to visit us. Luckily, you never did become 
part of our office, otherwise I would have gone crazy with the nonstop chit-chat between 
you and Cansu. That said I did appreciate your presence most of the times, even though I 
admittedly was a bit too mean sometimes (sorry, not sorry, for that). I am grateful for the 
times you helped me out with my experiments. While things didn’t work out at the EMC, 
I’m pretty sure you’ll do fine in the LUMC, and I hope I’m also invited for your PhD ceremony 
when that time arrives!! Michiyo, you were one of the most polite officemates I had, and 
it was so much fun talking to you about Japan, and even going out and eating Ramen with 
you and the rest of the gang. Farshid, thank you for providing me a lot of career advice, and 
welcoming me into your office that you were already sharing with Lucilla, who always had 
a story or two to tell. 
I still have many people to thank, and I’d like to continue with the technicians in the Delwel 
Group. Claudia and Andrea, thank you for the pleasant and very considerate conversations, 
you guys were always nice to me. Andrea one day we will definitely attend a salsa party or 
bachata event with one of my good friends, ahah. Marijke, bedankt voor jouw hulp in het 
ML-II lab. Ook wil ik de andere technici van onze afdeling bedanken, in het bijzonder Hans 
en Dennis; ik vond de bierproeverij en andere sociale evenementen altijd goed geslaagd, 
alleen was het jammer dat ik geen pittige ketchup meer van jullie kon krijgen. Inge, ik ben 
je ook dank verschuldigd, jij had me geholpen met het verwerken van muizen-botten voor 
immuno-kleuringen, nog bedankt hiervoor! 
I also want to thank former and current Post-Docs in the lab, Julien (also magic cola lol), 
Ferry, Leonie, Jess, and Nils. Thank you for all the times you helped me out with FACS-
sorting, providing general career advice, engaging scientific discussions, or just exchanging 
simple pleasantries. 
I also owe a lot to the (PhD-)students that have come before me. Very special thanks to Kasia 
and Jana, original founders of the EMC-techno club, it was such a blast to get to know the 
playful side of my fellow colleagues of the lab, and much respect to you OGs for setting the 
tone for the younger generation. I’d like to give even more props to Jana for introducing me 
to her fellow MolMed students. And thank you Kasia for giving me not only career advice, 
but also advice about life in general. Monica you deserve a special mention as well, you 
also helped me out a couple of times with FACS-sorting, and you were also very fun to party 
with, especially with Julien, I hope you are doing well in Vancouver! Shout-out to Patricia 
D (you also had a very fine musical taste), and Marshall, hope you are doing well in MAGA-
land! As for you, Roberto, I hope our lengthy conversations, which still have continued and 
hopefully will keep on going for a long time, made it clear how much I appreciate having you 
around. You have also been very considerate of others, in addition to being a deep-thinker 
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without ever being pretentious or arrogant. Having you and Adrian as roommates was so 
much fun, and I’m happy we managed to arrange this and experience so many, as you put 
it, “moments” together. Cause in the end, that’s all what matters no? I wish you all the 
best, and hopefully I will see you again soon. Perhaps one day we can all see Solar Fields 
together? Ostia. 
I also want to thank the other PhD students that are close to graduating or are getting 
there: Davine, Tim, Patricia O, Adil, Sophie, and Roger, zet hem op! I wish you the best with 
finishing your studies. To the newer PhD students that I have gotten to know a bit: Bella 
totally awesome that you returned to Hematology, hope you keep listening to good indie 
music, and perhaps I’ll bump into you in one of those random ADE parties. Madelon, het 
was leuk om je te leren kennen tijdens de Python cursus, houd me op de hoogte als je ooit 
een documentaire heb geregisseerd! Verder wens ik je nog succes met Paola in je kantoor, 
ik ben er heel bewust van dat ze best veel kan praten J. 
Ik wil ook nog andere collega’s van de afdeling Hematologie bedanken: Ans, Annelies, 
Eaudia, Tessa, en Leenke, ik wil jullie bedanken voor het regelen van al mijn afspraken met 
Marc en Ivo, verder waren jullie altijd behulpzaam als ik vragen had, bijvoorbeeld over hoe 
ik bepaalde reagenten het beste kon verzenden. Egied, ik wil jou ook hartelijk bedanken 
voor al jouw hulp met mijn proefschrift, zonder jou zou ik de tijd niet hebben gehad om 
mij goed te concentreren op mijn schrijfwerk. Verder ben ik heel tevreden over hoe mijn 
proefschrift eruit gaat zien. 
Over the years I also met a lot of fellow students outside of Hematology that made my 
EMC-experience all the more fun! Special thanks to Lena, I enjoyed our talks about free will/
determinism, you playing my musical requests during your DJ-set at BAR, and not to forget 
the many karaoke events! You also helped me realize that for some reason most of the cool 
people from Greece are from Thessaloniki, case in point Irene and Isabella! I had a great 
time with you girls at BKS, and many other events, perhaps we can find another festival 
soon. Maybe the one Ping will be attending this August, the music won’t be Radiohead or 
The Cure, but it I’m pretty sure it will be awesome! I also want to wish you both good luck 
with your PhDs. Also a special thank you to Irene for introducing me to the girl who took 
over your old room, haha. Also please give some hugs and kisses to Nefeli and Len for me! 
I also want to thank another expat from Thessaloniki, Simy, especially for giving me plenty 
of extra discounts at the EMC-cafeteria, good look with your egg studies! I also want to 
mention Anika and Liz, you guys were one of the first master students I started to hang out 
with when I first started out at the EMC. Thanks for having me over in Atlanta Liz, and I wish 
you good luck at the CDC! Anika good luck finishing up your PhD in Switzerland, and get that 
€€€. Also shout-out to the people I met from Infection & Immunology, Jurre, Anusha, and 
Simone who were always up for parties! I’d also like to give special thanks to the people 
form MolMed-school, Rodrigo and Pablo it was fun playing basketball with you guys from 
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time to time, and having many BBQ sessions (in the park)! Diana and Adna, you guys also 
joined for basketball a couple of times and even more special, I really had great time visiting 
you guys in your home countries and showing me around. I think it made me understand 
you guys better knowing where you came from, I guess haha. Diana, I wish you good luck 
in Memphis, just don’t get shot by those crazy Americans okay? Adna, hopefully you can 
manage finding a position in the EU and maybe see you at Tania’s and Alex’ wedding?! Very 
special thanks to these lovebirds for letting me stay at your place, so many times. It really 
felt like my third home. And besides that it has been so much fun going to (karaoke-)parties 
and festivals, such as Expedition and Bangface, with you guys. Take care of each other, and 
also good luck with writing your thesis Tania! 
The fun was not limited to the EMC, and I also have to mention some other awesome 
people, in particular the my fellow Bisons. Special thanks to Raz who has been the driving 
force behind all the awesome Bisons events. Shout-out to Ian, maybe the craziest Bison 
of them all, and that says a lot considering I know Adrian. I also want to thank Lorenzo, 
Thomas, Livia, Matteo, the Italian (Schopare?) branch of the Bison group, thanks for all the 
memorable parties and BBQs in the park.
Ik heb gelukkig nog meer vrienden, denk ik, onder andere Esther en Sanders, die ik ook wil 
bedanken voor het bijwonen van allerlei concerten, en hopelijk blijft dit ook de komende jaren 
zo doorgaan. Alleen moet DIIV wel weer goede muziek maken. Ik moet natuurlijk de Lamers-
squad ook opnoemen, zonder jullie zou ik mij veel minder hebben vermaakt de afgelopen 
jaren, vooral bedankt voor jullie geduld met mijn trollings, in het bijzonder Nilton en Kachon 
(die het ook vaak verdienen). Jullie hebben mij regelmatig geholpen met verhuizen, en ik 
ben eigenlijk de tel kwijt, thanks boys. Nahuel en Ali, cool dat jullie naar IJsland mee waren 
gekomen, kom maar nog een keer, alleen wel met extra verzekering voor de huurauto. 
Ik ben nu wel betere driver, of niet Nahuek? Verder GG met alle gaming sessies, en kom 
snel weer een paar potjes PES doen. Shout-out to fellow OG SXM’r strongman Rugene, I 
appreciated your heavy-lifting, not only during my moving, but also during my mom’s. It 
was also cool playing Pokemon Go with you for a bit, and I wish you the best in becoming 
a Pokemon master, if not yu-gi-oh/salsa/bachata master. Oh ja, ik wil ook nog succes aan 
Shiraaz toewensen met het afronden van jouw PhD. Ik wil nog één speciaal iemand van het 
EMC bedanken, en dat is Frank van Vliet, dank je voor al die keren dat je naar me luisterde 
over mijn problemen, advies hebt gegeven, fondsen voor mij hebt geregeld, en ook gewoon 
de gezelligheid die jij altijd aanbood met ons etentjes en drankjes. Hopelijk doe jij zelf de 
komende tijd ook rustig aan en hoef jij het niet zo druk te hebben met werk.
Ik wil ook even mijn familie bedanken, waaronder mijn neven en nichten, Bryan, Edsard, 
en Amy, wat leuk dat oma ons allemaal heeft weten samen te brengen, door haar hebben 
we allerlei familie-uitjes kunnen maken afgelopen tijd. Wel jammer dat we voorlopig niet 
veel kunnen tot 1 juni, maar ik weet zeker dat we daarna snel iets vinden om mijn promotie 
goed te vieren. Verder echt tof dat je nog mee was gekomen naar Malta Bryan toen we 
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Roberto opzochten, alleen volgende keer niet zo goedkoop parkeren in Eindhoven! Sowieso 
nog bedankt dat je me paranimf wil zijn! Verder wil ik ook mijn zusje Abygail bedanken, jij 
hebt me zo vaak moeten ophalen bij het vliegveld als er weer eens problemen waren, zelfs 
ook helemaal uit Brussel. Ook heb je vaak andere dingen voor mij gedaan en vervoerd, 
bijvoorbeeld wanneer mama eten wilde langsbrengen. Ik zal mijn best doen om aardiger 
tegen jou te zijn, en ook vaker bubbeltea meennemen naar huis voor jou. Ik wens je nog 
succes met het afronden van je studie. Ma, bedankt voor al het eten, en alle ontelbare 
dingen die jij voor mij hebt geregeld. Jij hebt misschien gelijk dat ik vaker naar je moet 
luisteren, maar ik zal altijd koppig blijven. Ik ben wel dankbaar naar jou en papa, dat jullie 
Abygail en mij naar Nederland hebben gebracht, want uiteindelijk hebben we hier een heel 
goed leven weten op te bouwen. Pa, ook bedankt voor al je aanmoedigingen en steun, 
onder andere door telkens te vragen wanneer mijn proefschrift af zal zijn. Het is eindelijk 
gelukt. 
And to cap it all off, I want to also to give special thanks Nina, my cutiepie. I have put you 
through a lot all these years of me trying to obtain my PhD title. Still the longer you waited 
the more I felt I had to finish; otherwise that waiting would have been for nothing. Luckily 
you are very patient (haha) and the time has finally arrived that we can take the next step, 
not only in our career, but life in general. I want to thank you for hanging in there, and also 
for the pretty cover you and your friend Lydia, made for me. Where-ever our adventures 
may lead us, I hope I’ll be good enough to stand by your side. 
Well that’s it, I probably forgot to mention a couple of people, and for that I have to apologize, 
but I need to print this dissertation in time, kthxbye.  
Addendum
